The Role of VTA Gabaergic Nicotinic Acetylcholine Receptors Containing the α4 Subunit in Nicotine Dependence: A Dissertation by Ngolab, Jennifer
University of Massachusetts Medical School 
eScholarship@UMMS 
GSBS Dissertations and Theses Graduate School of Biomedical Sciences 
2015-10-06 
The Role of VTA Gabaergic Nicotinic Acetylcholine Receptors 
Containing the α4 Subunit in Nicotine Dependence: A Dissertation 
Jennifer Ngolab 
University of Massachusetts Medical School 
Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/gsbs_diss 
 Part of the Neuroscience and Neurobiology Commons, Psychiatry and Psychology Commons, and the 
Substance Abuse and Addiction Commons 
Repository Citation 
Ngolab J. (2015). The Role of VTA Gabaergic Nicotinic Acetylcholine Receptors Containing the α4 Subunit 
in Nicotine Dependence: A Dissertation. GSBS Dissertations and Theses. https://doi.org/10.13028/
M2730B. Retrieved from https://escholarship.umassmed.edu/gsbs_diss/851 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in GSBS Dissertations and 
Theses by an authorized administrator of eScholarship@UMMS. For more information, please contact 
Lisa.Palmer@umassmed.edu. 
 THE ROLE OF VTA GABAERGIC NICOTINIC ACETYLCHOLINE RECEPTORS 
CONTAINING THE α4 SUBUNIT IN NICOTINE DEPENDENCE 
A Dissertation Presented 
By 
Jennifer Ngolab 
Submitted to the Faculty of the University of Massachusetts 
Graduate School of Biomedical Sciences, Worcester 
in partial fulfillment of the requirements for the degree of 
DOCTOR OF PHILOSOPHY 
October 6th, 2015 
NEUROSCIENCE 
 
 
 
 
 
 
 
 
 
 
 ii 
THE ROLE OF VTA GABAERGIC NICOTINIC ACETYLCHOLINE RECEPTORS 
CONTAINING THE α4 SUBUNIT IN NICOTINE DEPENDENCE 
A Dissertation Presented By 
Jennifer Ngolab 
The signatures of the Dissertation Defense Committee signify completion and 
approval as to style and content of the Dissertation 
    
             
Andrew R. Tapper/ Paul D. Gardner, Thesis Advisors 
             
Michael Francis, Member of Committee 
             
Fen-Biao Gao, Member of Committee 
             
Jean King,  Member of Committee 
             
Ralph Loring,  Member of Committee 
The signature of the Chair of the Committee signifies that the written dissertation 
meets the requirements of the Dissertation Committee  
             
David Weaver,  Chair of Committee 
The signature of the Dean of the Graduate School of Biomedical Sciences 
signifies that the student has met all graduation requirements of the school.  
             
Anthony Carruthers, Ph.D.,  
Dean of the Graduate School of Biomedical Sciences 
 
Neuroscience 
October 6th, 2015 
 iii 
ACKNOWLEDGEMENTS 
When I think back at how much I have accomplished, I realize that I would not 
have been able to do so without the help of my mentors, my labmates, my friends 
and family.  First, I would like to thank my mentors, Andrew R. Tapper and Paul 
D. Gardner, for taking a chance on me.  Andrew provided the stern guidance I 
needed when I wanted to do everything at once and when I was at my wits end.  
Paul imparted sage tidbits of advice that I will heed carefully throughout my 
career.  I will continuously look up to them, as their intellect and overall character 
is something I will still aspire to reach.     
I would also like to acknowledge my TRAC committee members, David Weaver, 
Michael Francis and Fen-Biao Gao for their thoughtful input into my thesis work 
throughout the years and helping me grow as a scientist. 
Second, I would like to thank the many lab members of the Tapper/Gardner lab, 
both past and present.  I have witnessed many people come and go, yet when I 
reminisce, it feels like it was only yesterday that they were here.  Many of the 
senior graduate students offered sage advice about how to handle classes, 
experiments and my mentors’ temperaments. It was assuring to know I had 
someone to turn to for support, whether or not it was science related or not did 
not matter.  I’d like to take the time to recognize Eric Hogan, a lab member who 
left too soon.  His passion for science was what drew me to the lab, and I 
continue to attempt to emulate that passion in his memory. 
I would also like to thank the many friends I have made out here during my time 
in Massachusetts.  To my core group of graduate school friends that stuck with 
each other since our first year in core, Sharanya, Yuxin, Xiaoming, Cassie and 
Ngoc: thank you for being there to share the highs and lows of graduate school.  
Thank you for being there when I needed help and helping me get used to life out 
here. 
Lastly, I would like to thank my parents, Brandon and Hilaria Ngolab and my two 
older brothers, Mark and Kirk Ngolab. I really cannot thank them enough- for they 
assisted me on my move here, provided me with attention when I needed it and 
gave me encouragement when I needed it the most.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 iv 
ABSTRACT 
Nicotine dependence is hypothesized to be due to neuroadaptations that 
ultimately drive compulsive nicotine use.  The studies in this thesis aim to 
understand how the “upregulation” of nicotinic acetylcholine receptors (nAChRs) 
caused by chronic exposure to nicotine contributes to nicotine reward and 
nicotine withdrawal.  Previous studies have shown that chronic nicotine induces 
upregulation of nAChRs containing the α4 subunit (α4* nAChR) within the 
Ventral Tegmental Area (VTA), a brain region critical for the rewarding properties 
of all illicit drugs.  Curiously, α4* nAChR upregulation occurs specifically in the 
inhibitory GABAergic neuronal subpopulation of the VTA. To determine if 
increased expression and activation of α4* nAChRs in VTA GABAergic neurons 
contributes to nicotine dependence behaviors, I devised a viral-mediated, Cre-
regulated gene expression system that selectively expressed α4 nAChR subunits 
containing a “gain-of-function” point mutation (a leucine mutated to a serine 
residue at the TM2 9´ position: Leu9´Ser) in VTA GABAergic neurons of adult 
mice.  Sub-reward doses of nicotine were sufficient to activate VTA GABAergic 
neurons in mice expressing Leu9´Ser α4 nAChR subunits in VTA GABAergic 
neurons (Gad2VTA: Leu9´Ser mice) and exhibited acute hypolocomotion upon 
initial injection of low doses of nicotine that developed tolerance with subsequent 
nicotine exposures compared to control animals.  In the conditioned place 
preference procedure, nicotine was sufficient to condition a significant place 
preference in Gad2VTA: Leu9´Ser mice at low nicotine doses that failed to 
condition control animals.  I conclude from these data that upregulating α4* 
nAChRs on VTA GABAergic neurons increases sensitivity to nicotine reward.  In 
a separate study testing the hypothesis that overexpression of Leu9´Ser α4* 
nAChRs in VTA GABAergic neurons disrupts baseline behavior and promotes 
anxiety-like behaviors, I found that overexpressing Leu9´Ser α4* nAChRs in VTA 
GABAergic neurons had a minimal effect on unconditioned anxiety-like 
behaviors.  Drug naïve Gad2VTA: Leu9´Ser and control mice failed to exhibit any 
behavioral differences in the open-field, marble burying test and elevated plus 
maze compared to control.   
Together, these data indicate that overexpression of the “gain-of-function” α4* 
nAChRs in VTA GABAergic neurons contributes to reward sensitivity without 
increasing susceptibility to nicotine withdrawal symptoms.  My data indicates that 
nAChRs expressed in VTA GABAergic neurons may be a suitable target for the 
development of better smoking cessation aids.   
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CHAPTER I. 
INTRODUCTION 
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I.A. – Nicotine Dependence 
Long-term cigarette smoking reduces the quality of life for the smoker and those 
around them (Jha et al., 2013; USDHHS, 2014).  Multiple studies indicate that 
smoking increases the risk for diabetes, lung cancer and coronary maladies.  In 
fact, it is estimated that every year more than 5 million deaths are attributed 
alone to smoking related complications (USDHHS, 2014).  It is estimated that 
smoking subtracts a decade from total life expectancy while quitting can restore 5 
years (Jha et al., 2013).  Second hand smoke can cause sudden infant death 
syndrome in children and contribute to the risk of developing coronary heart 
disease and lung cancer in adults (USDHHS, 2014).  Despite being the leading 
preventable cause of death and disability and 50 years of advocating against the 
practice, around 42.1 million people in the United States still smoke (USDHHS, 
2014).    
Nicotine is the addictive substance in tobacco (Stolerman and Jarvis, 1995).   It is 
as addictive, if not more, as heroin and alcohol and takes as few as 100 
cigarettes to develop dependence (USDHHS, 2014).  Humans experience a mild 
positive reinforcing response to nicotine, described to be slightly euphoric and 
relaxing (Henningfield et al., 1985; Pomerleau, 1992; Stolerman and Jarvis, 
1995; Benowitz, 1996).  Nicotine readily enters the bloodstream through the 
lungs and crosses the blood brain barrier within 8 to 10 seconds after inhalation 
(Benowitz and Jacob, 1990; Matta et al., 2007).  One inhalation of a cigarette 
induces a rapid influx of nicotine into the blood (Henningfield and Benowitz, 
1995; Nides, 2008).  While nicotine routinely remains in the plasma for 3 hours, 
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smokers can retain nicotine in the plasma for up to 20 hours (Matta et al., 2007).  
Smokers are able control the amount of nicotine through the amount of puffs they 
inhale from a cigarette, giving them the ability to control the buzz they 
experience.   
Nicotine dependence is a complicated behavior composed of three-phases:  1) 
acquiring and maintaining constant nicotine-taking behavior, 2) exhibiting 
negative withdrawal symptoms while not using and 3) increasing vulnerability to 
relapse (D’Souza and Markou, 2011).  These stages presumably reflect 
neurobiological adaptations in response to constant nicotine consumption.  While 
nicotine has positive properties, it is hypothesized that the adverse symptoms 
experienced during acute nicotine withdrawal primarily motivate relapse.  The 
onset of symptoms ranges from 4 to 24 hours after the last cigarette consumed 
(McLaughlin et al., 2015).  Somatic or physical symptoms include dry mouth and 
body tremors while affective or psychological symptoms include anxiety, 
irritability and inability to focus (Hughes, 1999).  Nicotine withdrawal symptoms 
peak within the first week and can last up to four weeks (Hughes, 2007).  The 
intensity of negative affective symptoms experienced during withdrawal can 
predict the likelihood to relapse (Piasecki et al., 2000).   While long-term nicotine 
use causes changes in the brain such as changes in neurotransmission and 
receptor expression, it is unknown how these neuroadaptations contribute to 
negative withdrawal symptoms.  Another line of evidence for long-term 
neuroadaptations following chronic nicotine exposure is the susceptibility to 
relapse even after years of abstinance.  
 4 
Negative stressors, or stimuli that are perceived to be harmful or challenging, are 
a major contributor to drug relapse (Sinha, 2008, 2009; Bruijnzeel, 2012).  
Studies in humans and animals have determined that chronic stress coincided 
with heightened vulnerability to drug dependence, especially in adolescence 
(Sinha et al., 2001, 2008; Burke and Miczek, 2014).   The emotional value of a 
particular stimulus can trigger relapse.  Stressful cues induced drug craving, both 
in cocaine (Sinha et al., 1999) and nicotine dependent individuals (Michalowski 
and Erblich, 2014).  Furthermore, laboratory experiments that aggravated stress 
in withdrawn smokers observed a decreased resistance to smoke and longer 
smoking consumption (Mckee et al., 2011).  Chronic nicotine can also heighten 
physiological response to stress during withdrawal (Tsuda et al., 1996).  Due to 
the contributions of stress to relapse, it is important to also understand how 
nicotine factors into the mechanisms behind stress-induced relapse.  
Maintaining abstinent from cigarettes is often difficult for smokers, despite their 
well-meaning intents.  In a 2010 survey, 68.8% of smokers expressed the 
intention to quit; yet only 6.2% of those surveyed reported to have quit within the 
year (CDC, 2011).  51.2% of smokers that attended a smoking cessation clinic 
relapsed within a year, further emphasizing the difficulty of remaining abstinent 
even after seeking help (Kocak et al., 2015).   
Current first-line therapeutics available to help aide smokers to quit includes 
nicotine replacement therapies (NRT), buproprion (Zyban®) and varenicline 
(Chantix®).  Nicotine replacement therapies administer nicotine at concentrations 
lower than what is obtained through cigarettes to wean a smoker from the 
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reinforcing effects of nicotine.  NRTs come in different forms, from lozenges to 
skin patches, with similar efficacy (Nides, 2008).  However, NRTs do not deliver 
nicotine at the same rate as smoking a cigarette, which may account for the 
dissatisfaction that smokers express when on NRTs and could discourage 
continued use (Henningfield, 1995).   With non-nicotine therapies, as many as 
44% of smokers remained abstinent after 12 weeks on varenicline compared to 
28.9% on buprorion and 17.7% on placebo (Gonzales et al., 2006; Jorenby et al., 
2006).   However, the percentage of smokers that remained abstinent while on 
varenicline decreased to 20-25% within one year of treatment (Gonzales et al., 
2006; Jorenby et al., 2006).  Furthermore, current smoking cessation 
therapeutics are minimally successful in mitigating nicotine withdrawal symptoms 
(Cinciripini et al., 2013; Foulds et al., 2013; Turner et al., 2013).  Even with the 
Food and Drug Administration approval of varenicline in 2006 as a smoking 
cessation agent, annual smoking cessation rates changed from 4.5% in 2003 to 
4.7% in 2010 (Zhu et al., 2015).  Overall, the available therapies provide 
temporary relief, but are not sufficient to maintain long-term abstinence.  Better 
understanding of the biological mechanisms behind nicotine dependence, such 
as the substrates nicotine binds onto, would help with the development of better 
aids for smoking cessation. 
 
I.B. - Nicotinic acetylcholine receptors  
The nicotinic acetylcholine receptors (nAChRs) are ligand-gated cation channels 
that are endogenously bound by the neurotransmitter acetylcholine as well as 
nicotine.  They are a part of the Cys-loop receptor superfamily that also contains  
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the GABAA, glycine and the 5-HT3 receptor. nAChRs are composed of five 
subunits arranged to form a pore that permits ions to flow down their 
electrochemical gradient.  Twelve unique nAChR subunits have been identified, 
including nine α subunits (α2-α10) and three β subunits (β2-β4) (Luetje and 
Patrick, 1991; Covernton et al., 1994; Chavez-Noriega et al., 1997; Kuryatov and 
Lindstrom, 2011).  Each subunit contains an amino extracellular terminus that 
contributes to the ligand binding pocket, four membrane spanning domains, of 
which the second transmembrane domain (TM2) lines the pore and forms the 
channel gate, and a large variable intracellular loop (Figure I-1 A) (Albuquerque 
et al., 2009).  There are specific cysteine residues along the extracellular amino 
terminus that play an important role in the identification and the function of the 
subunit.  The ligand-binding site is composed of the hydrophobic pocket formed 
by a cysteine disulfide bond on the alpha subunit and the backside of the 
adjacent subunit (Albuquerque et al., 2009) (Fig I-1B, red triangles).  A pair of 
cysteine residues in the extracellular amino terminus close to the first 
transmembrane domain (TM1) distinguishes an alpha subunit from a beta 
subunit (Lukas et al., 1999) (Fig I-1A, red dots).  The nAChR subunits can 
coalesce with either five identical subunits to form homomeric receptors, or 
combine with both alpha and beta subunits to create heteromeric receptors 
(Figure I-1 B) (Cooper et al., 1991).  The receptor subunit combination 
determines the biophysiological and pharmacological properties.  For example, 
α4β2* nAChRs can exist either as (α4)3(β2)2 or (α4)2(β2)3 stoichiometry (the 
asterisk denote that other subunits may be present in the receptor) (Nelson et al., 
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2003; Kuryatov et al.,  2005).  Studies done in Xenopus oocytes determined the 
former stoichiometry forms low sensitivity receptors and the latter confers high  
 
Figure I-1. Neuronal nAChRs  structure and function   A) Structure of the nAChR 
subunit.  Each subunit is composed of four transmembrane domains (TM1-TM4), 
a large extracellular amino tail that is responsible for ligand binding, and an 
intracellular variable loop connecting TM3 to TM4.  Highlighted in red are 
cysteine residues on the extracellular amino tail that form a cys-loop found in all 
subunits and the cysteine doublet that distinguishes α from β nAChR subunits.  
B) Representative nAChR subtypes, including receptors composed of identical 
nAChR subunits (homomeric) and nAChRs composed of a variety of nAChR 
subunit (heteromeric).  The red triangles represent the binding site formed by the 
α nAChR cys-loop and the adjacent subunit.  C) Possible conformations of 
nAChR.  Receptors that are not bound by agonist are considered to be in the 
‘resting state’, where the pore of the channel is closed.  When agonist such as 
acetylcholine or nicotine (represented by the yellow hexagon) binds onto a 
nAChR, the receptor is ‘activated’ the pore is open.  The ‘desensitized’ state is 
when the pore remains closed despite being bound to agonist (Figures 1A and B 
were adapted from  Hendrickson et al., 2013, 1C is adapted from Changeux, 
1984).  
 
	
             
subun t   Each su u it is com osed o  f ur t ansme ane domain  (T 1- M2 , 
a arg  ex racell lar amino ail h t s esponsible fo  l g n  ndi  a 
rac ular M3-T 4 variable oop   igh ighted resid es o  e ex r el u ar 
a no ail epresent he c s-loop oun  i  a  su un t  nd e cys-c s air  
distingu shes α f  β nACh  s buni s   B) Represe a ive n ChR s b y es, 
i c udin  re ept rs composed of en ica  AC R u ni  omom ric) and 
ChRs compos  o  a ariety of ACh  su unit e e ome ic).  C) ossible 
o or ations  nAC .  ece o s tha  are o  ou  y a o s  e 
co s dered to be i  e res i  a e , here the o e o  he ha el is c o d.  
hen ag is  suc  as ace y c o ine o  co  epresent  y he ell  
h ag ) i  ont  a C , t e ecep  i  a iva e  he pore is ope    
‘de itiz  t e is  e  e in  o  spi  g b u d o 
gonis  (Fig e   a   re da t    d i k  t l , 20 3 .  	
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sensitivity receptors (Nelson et al., 2003; Tapia et al., 2007).  Furthermore, 
different nAChR combinations, or subtypes, are expressed in selected 
subpopulations in the brain.  While α4β2* and α7 nAChRs are ubiquitously 
expressed throughout the brain, nAChR subunits such as the α6, α5 and β4 are 
found in distinct brain regions such as the interpeduncular nucleus (IPN) and 
medial habenula (MHb) (Klink et al., 2001).  These properties of nAChR 
expression and function provide a challenge to identifying an effective target for 
nicotine dependence.    
Chronic nicotine treatment can alter the expression and function of nAChRs.    
Prolonged exposure to agonist causes nAChRs to desensitize, or no longer 
respond to agonist (Quick and Lester, 2002) (Figure I-1 C).  Desensitization 
occurs immediately after channel opening, although activation of the receptor is 
not always required (Changeux et al., 1985; Giniatullin et al., 2005).  The 
desensitization properties of a nAChR are highly dependent on the nAChR 
subtype, as α7 nAChRs quickly desensitize compared to other subtypes while 
α4β2* nAChRs desensitize at low concentrations of agonist (Couturier et al., 
1990; Pidoplichko et al., 1997).  Ligand binding affinity is higher in desensitized 
nAChRs compared to their active counterparts (Quick and Lester, 2002).  This 
fundamental characteristic of nAChRs could factor into certain aspects of nicotine 
dependence.  For example, it is hypothesized that smokers continue to smoke in 
order to maintain nAChR desensitization (Brody et al., 2006).   
 9 
 
Figure I-2. Sequence and structure of the α4 nAChR subunit TM2 domain.  A) 
Amino acid sequence of the endogenous (α4 WT, top) and Leu9’Ser nAChR 
(middle) TM2 region of the α4 nAChR subunit.  (Bottom) Schematic depicting  
each nAChR subunit domain along the sequence of the CHRNA4 sequence.  B) 
Proposed alignment of TM2 residues within a nAChR pore.  Two α4 nAChR TM2 
domains subunits are in view.  It is proposed that the 9’ leucines from the five 
nAChR subunits form a gate within the ion pore (Adapted from Revah et al., 
1991).   
 
A neuronal compensatory mechanism that occurs with chronic nicotine use is the 
upregulation of nAChRs.  “Upregulation” encompasses all changes in nAChR 
expression that result in the increased expression and function of nAChRs, 
including increasing receptor number, decreasing the rate of degradation of 
particular receptors and changing subunit stoichiometry within a receptor (Nelson 
et al., 2003; Kuryatov et al., 2005; Srinivasan et al., 2011; Govind et al., 2012).  
Multiple studies from rodent to human have observed that the subtype commonly 
upregulated is α4β2* nAChR subtype in the (α4)2(β2)3 conformation (Flores et 
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al., 1992; Nashmi et al., 2007; Staley et al., 2006; Muhkin et al., 2008).  
Increased nAChR expression due to chronic nicotine can last up to 7-21 days 
after the last nicotine exposure (Marks et al., 1983; Schwartz and Kellar, 1985; 
Staley et al., 2006; Hilario et al., 2012).  Much is known about the molecular and 
cellular underpinnings of nAChR upregulation (Henderson and Lester, 2015), yet 
how upregulation of nAChRs contributes to nicotine dependence behaviors is not 
well understood.  When factoring in the contributions of desensitization of 
nAChRs and nAChR upregulation, one can appreciate the level of complexity of 
nicotine dependence at the receptor level. 
To determine where the functional domains on the nicotinic acetylcholine 
receptor subunit reside, individual residues along the amino acid sequence were 
mutated via site directed mutagenesis.  Viable mutant receptors were then 
assessed through biophysical techniques in vitro to determine how the mutated 
residue affected receptor dynamics. Point mutations to the TM2 of the α1 nAChR 
decreased binding of QX-122, an open-pore blocker, highlighting the role of 
these particular residues in forming the nAChR pore (Leonard et al., 1988).  
Another study mutated the 9´ leucine in TM2 of the α7 nAChR subunit to a serine 
and observed decreased receptor desensitization rates, increased sensitivity to 
agonist and the lack of a rectifying current (Revah et al., 1991). Subsequent 9´ 
leucine to serine mutation (Leu9´Ser) in muscle and α4* nAChRs conferred 
nAChRs with similar characteristics (Labarca et al., 1995, 2001) (Figure I-2A).  
Together, these studies helped identify key regions of the nAChR important for 
receptor function.   The  9´ leucine is highly conserved amongst nAChR subunits 
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(Lester 1992; Betz 1990) and is thought to form the gate of the ion pore (Figure I-
2 B).  Mutating the 9´ leucine increases the permeability of the channel, therefore 
allowing ions to move along their electrochemical gradient while in the high 
affinity desensitized state (Revah et al., 1991).  This confers nAChRs with the 
Leu9´Ser mutation hypersensitive to agonist.  These data paved the way for the 
development of a novel method to study specific nAChR receptor function in vivo 
through genetic mouse models (Labarca et al., 2001; Tapper et al., 2004; Fonck 
et al., 2005). 
 
I.C. Mesocorticolimbic Dopaminergic  Pathway  
It has been well established that the mesocorticolimbic DAergic pathway is a 
major component in goal-oriented behavior (Wise, 2004).  Composed of the 
ventral tegmental area, the nucleus accumbens (NAc) and the prefrontal cortex 
(PFC), this pathway critical in the development of nicotine dependence (D’Souza 
and Markou, 2011) (Figure I-3). Multiple drugs of abuse, including nicotine, 
manipulate the activity of the mesocorticolimbic DAergic pathway through the 
ventral tegmental area to increase DA concentration in the NAc, which is 
considered a hallmark of brain reward (Di Chiara and Imperato, 1988).  
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Figure I-3.  The mesocorticolimbic dopaminergic pathway.  Simplified schematic 
of the Ventral Tegmental Area (VTA) microcircuitry, with emphasis on the 
neuronal subpopulations within the area.  The VTA receives glutamatergic, 
GABAergic and cholinergic (ACh) inputs from multiple brain regions.  These 
inputs can innervate the dopaminergic (DA) and GABAergic subpopulations of 
the VTA.  The DAergic neurons project to the nucleus accumbens (NAc), forming 
the mesolimbic DAergic pathway, or the prefrontal cortex (PFC), forming the 
mesocortical DAergic pathway.  Glutamatergic projections from the PFC have 
been found to influence VTA activity.  The GABAergic portion of the VTA is 
comprised of interneurons that influence DAergic activity or projection neurons 
that act upon the NAc, PFC and lateral habenula (LHb).   
 
 
The Ventral Tegmental Area 
The Ventral Tegmental Area (VTA) is a heterogeneous population of neurons 
located in the ventral midbrain (Roeper, 2013; Pistillo et al., 2015).  This dense 
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group of cells is composed of dopamine (DA) neurons as well as neurons that 
release Υ-aminobutyric acid (GABA) (Dahlstroem and Fuxe, 1964; Olson and 
Nestler, 2007; Nair-Roberts et al., 2008; Yamaguchi et al., 2011) (Figure I-3 A).  
It is becoming increasingly apparent that different groups of DAergic neurons are 
segregated according to location (Lammel et al., 2012, 2015) while there is no 
consistent subpopulation organization in GABAergic neurons (Chieng et al., 
2011). Recent studies identified a subset of VTA neurons, including DAergic 
neurons, express vesicular glutamatergic transmitter 2 (VGLUT2) and therefore 
can release the major excitatory neurotransmitter glutamate (Yamaguchi et al., 
2007, 2011, 2015; Hnasko et al., 2010, 2012).  Studies are ongoing to discern 
how VTA glutamatergic neurons modulate motivated behavior (Yoo et al., 2015).  
Distinct nuclei reside within the VTA, including the paranigral nucleus, the 
parabrachial pigmented nucleus and the interfasicular nucleus (Ikemoto, 2007).   
Furthermore, the VTA can be roughly sectioned into three subregions along the 
coronal plane- the anterior, posterior and tail (or rostromedial tegmental nucleus- 
RMTg) (Perrotti et al., 2005; Ikemoto, 2007; Jhou et al., 2009, Sanchez-Catalan, 
2014), with distinct nuclei as well as the set of afferents and efferents 
distinguishing each VTA subregion (Pistillo et al., 2015).  
  
VTA Dopaminergic Neurons 
Dopaminergic neurons comprise about 60-65% of the VTA neuronal population 
(Yetnikoff et al., 2014; Pistillo et al., 2015).  Neurons in this subpopulation are 
identified through a distinct set of electrophysiological characteristics, such as 
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currents that contain a voltage sag, or an Ih current and spontaneous tonic pace-
maker firing activity as well as tyrosine hydroxylase (TH) immunoreactivity 
(Grace and Onn, 1989; Lacey et al., 1989).  Yet recent studies indicate that 
DAergic neurons in the VTA are not homogeneous (Margolis et al., 2008; Ford et 
al., 2006; Lammel et al., 2012, 2014).  The diversity of DAergic neurons provides 
a better framework for understanding how the VTA can be activated by 
rewarding, aversive and neutral stimuli (Schultz, 2010). 
Classic electrostimulation studies in rats have indicated the midbrain, particularly 
the DAergic neuron rich area, as an important region in reward and 
reinforcement behavior (Olds and Milner, 1955; Crow, 1971).  Complimenting 
these findings, studies in monkeys established that stimuli preceding reward 
activate midbrain DAergic neurons, specifically the A10 DAergic neurons 
(Schultz, 1986; Schultz et al., 1993).   Furthermore, self-administration studies 
have pinpointed the posterior VTA (pVTA), but not the aVTA, is important for 
reward signaling, for infusing drug into the pVTA increased reward behavior 
(Zangen et al., 2000; Rodd et al., 2005; Ikemoto et al., 2006).  Presentation of a 
reward stimulus caused DAergic neurons to exhibit bursts of activity, a classic 
pattern of activity often accompanied by dopamine release (Schultz, 1986; 
Schultz et al., 1993; Wightman and Robinson, 2002; Tsai et al., 2009).  DAergic 
neurons in the VTA project to other brain regions such as the NAc and PFC 
(Laviolette and van der Kooy et al., 2004; Ikemoto et al., 2007) (Figure I-2 B).  
Increased dopamine concentration in the NAc occurs in response to naturally 
occurring reward, VTA self-stimulation and drugs of abuse (Di Chiara et al., 
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1988; Hernandez et al., 1988; Damsma et al., 1992; Pfaus et al., 1993; Fiorino et 
al., 1993). Stimulating of VTA DAergic neurons at a frequency that mimics burst 
firing leads to DA release and conditioned place preference, further bolstering the 
argument that VTA DAergic neurons transduce reward (Tsai et al., 2009).  These 
data support the hypothesis that inducing burst-firing activity in the DAergic 
neurons of the VTA results in an increase of dopamine and reward signaling.  
 
VTA GABAergic neurons 
Neurons that release the neurotransmitter GABA, the major inhibitory 
neurotransmitter in the central nervous system make up about 20-35% of VTA 
(Chieng et al., 2011; Nair-Roberts et al., 2008; Yamaguchi et al., 2007). 
GABAergic neurons in the VTA have distinct biophysical characteristics that set 
them apart from DAergic neurons, such as fast action potential duration 
compared to DAergic neurons and do not have a slow depolarizing current seen 
in VTA DAergic neurons (Lacey et al., 1989, Johnson and North). Recent studies 
assessing the electrophysiological characteristics of VTA GABAergic neurons 
confirmed these criteria held true for the majority of GABAergic neurons with a 
minority of GABAergic neurons exhibiting an Ih current (Chieng et al., 2011).  The 
authors rationalize the electrophysiological differences may be due to location 
within the VTA, similar to what has been observed in VTA DAergic neurons 
(Lammel et al., 2014). The VTA receives cholinergic innervation primarily from 
the LDTg, with 65% of the cholinergic terminals forming synapses onto non-
DAergic neurons (Oakman et al., 1995; Garzon et al., 1999).  Therefore, 
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cholinergic innervation of GABAergic neurons plays a role in behaviors mediated 
by the LDTg.  About 25% VTA GABAergic neurons are projection neurons 
targetting other brain regions, such as the NAc, the PFC and the lateral habenula 
(LHb) (Carr and Sesack, 2000; Taylor et al., 2014) (Figure I-3 C). 
Much of what is known about VTA GABAergic neurons in the mesocorticolimbic 
DAergic pathway comes from experiments using either various GABAergic 
signaling blockers or opioid receptor antagonists. Opioids specifically reduce 
activation of non-DAergic neurons in vivo (Johnson and North, 1992).  These and 
other studies lead to the ‘disinhibition’ hypothesis: that is, when GABAergic 
neurons are inactivated to disinhibit DAergic neurons and promote reward 
signaling (Johnson and North, 1992; Mansvelder et al., 2002; Creed et al., 2014).  
Recent technological advances have allowed for the specific activation of 
GABAergic neurons located within the VTA to assess their role in behavior.  
Optogenetic activation of VTA GABAergic neurons disrupts reward behavior (van 
Zessen et al., 2012)  elicits aversion (Tan et al., 2012)  and modulates acquisition 
of reward (Brown et al., 2014).  Inhibiting VTA GABAergic neurons through 
halorhodopsin resulted in the disinhibition of DA neurons (Bocklisch et al., 2013).  
Furthermore, GABAergic neurons exhibit an intense spike in activity immediately 
after punishment, which coincided with an immediate decrease in VTA DAergic 
firing frequency (Cohen et al., 2012).  Overall, these data highlight a regulatory 
role for GABAergic neurons in the VTA in modulating DAergic transmission. 
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Afferents to the VTA 
The VTA receives glutamatergic, cholinergic and GABAergic input that regulates 
DAergic neurons and ultimately modulate motivated behaviors (Fig I-2) (Paolini 
et al. 2011; Li et al., 2014; Pistillio et al., 2015). Glutamate into the VTA can 
increase DAergic neuronal activity; initiate DAergic burst firing in vivo and 
increase DA concentrations in the NAc (Geisler et al., 2007; van Huijstee et al., 
2015). Innervation by glutamatergic projections from the PFC, the Laterodorsal 
Tegmentum (LDTg) and LHb activates VTA DA neurons (Murase et al., 1993; 
Lodge and Grace 2006; Lammel et al., 2012).  Additionally, the infusion of 
glutamate agonists into the VTA elevated DAergic firing frequency and incites DA 
burst activity (Johnson et al., 1992b; Chergui et al., 1993).  Drugs of abuse 
including nicotine increase glutamatergic receptors, particularly the ionotropic 
AMPA receptors.  As a result, the AMPA/NMDA ratio, a measure of synaptic 
strength, was increased in DAergic neurons 24 hours after drug administration 
(Saal et al., 2003). However, inactivation of the LDTg reduced DA burst firing 
even with the infusion of additional glutamate, suggesting other neurotransmitters 
from the LDTg such as acetylcholine contribute to DAergic burst activity (Lodge 
and Grace, 2006). The majority of VTA cholinergic projections originate in the 
LDTg (Cornwall et al., 1990; Oakman et al., 1995; Maskos, 2008).  Infusions of 
acetylcholine receptor antagonists into the VTA lessened NAc DA concentrations 
during LDTg electrostimulation, implying cholinergic transmission from the LDTg 
shapes VTA DAergic neurons (Forster and Blaha, 2000).  Delivering cholinergic 
antagonists into the VTA also decreases reward signaling (Corrigal et al., 1998; 
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Shinohara et al., 2015) and precipitated withdrawal, heavily implicating the 
importance of cholinergic transmission in affective behaviors.  The VTA also 
receives GABAergic innervation from the RMTg and the LDT (Perotti et al., 2005, 
Jhou et al., 2005).   RMTg neurons are activated by aversive stimuli, such as foot 
shock and food deprivation (Jhou et al., 2009).  Furthermore, RMTg GABAergic 
neurons synapse onto DAergic neurons, suggesting that RMTg neuronal 
activation decreases DAergic activation (Jhou et al., 2009).  It is interesting to 
note that psychostimulants activate the RMTg as determined by Fos 
immunoreactivity (Perrotti et al., 2005), for it suggests inhibitory input into the 
VTA contributes to the rewarding effects of these drugs.  Overall, afferents to the 
VTA can influence the VTA microcircuitry and drive DAergic activity to induce 
reward, while various drugs of abuse can alter neurotransmission to promote 
reward. 
 
Neuroadaptations within the VTA caused by chronic nicotine 
Chronic nicotine use instigates brain-wide neuroadaptations thought to drive the 
persistent consumption of nicotine (Koob and Volkow et al., 2008; D’Souza et al., 
2011; Jackson et al., 2012). Changes in receptor expression and 
neurotransmitter release within the VTA instigated by chronic nicotine use result 
in modified VTA DA transmission. NAc DA concentrations were significantly 
lower in nicotine-withdrawn rat brain slices compared to control (Zhang et al., 
2012).  Decreased NAc DA concentration due to hypofunctional DAergic neurons 
resulted in an anhedonic state that could factor into increased drug seeking 
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(Epping-Jordan et al., 1998; Tye et al., 2012).  Furthermore, an acute nicotine 
exposure induced a significant increase of DA released into the NAc of 
withdrawn rats compared to control (Zhang et al., 2012).  Chronic nicotine leads 
to increased expression of specific nAChR subunits in VTA DAergic neurons as 
well as glutamatergic receptors in the VTA and the NAc  (Nashmi et al., 2007; 
Kenny et al., 2009; Baker et al., 2012; Liechti et al., 2007a,b).  The overall result 
of the molecular and cellular changes brought forth by chronic nicotine exposure 
could induce a rapid influx of DA in a DA-deprived NAc that results in an intense 
rewarding signal that strongly drives relapse.  Precipitating nicotine withdrawal 
increases expression of Corticotrophin Release Factor (CRF), a neurotransmitter 
involved in stress signaling, within the central amygdala and the VTA  (George et 
al., 2007; Grieder et al., 2014).  It is hypothesized that CRF acts upon the IPN to 
elicit anxiety (Zhao-Shea et al., 2014), which would explain the increased 
negative affective symptoms experienced during nicotine withdrawal.    
 
nAChRs and the VTA 
Various drugs of abuse act upon presynaptic and post-synaptic components of 
the mesocorticolimbic pathway to increase dopamine concentrations (Luscher 
and Malenka 2011).  Nicotine acts upon the VTA to ultimately induce DAergic 
release into the NAc (Di Chiara and Imperato, 1988).  Expression of β2 and α4 
expression is necessary for nicotine-mediated DAergic activation (Picciotto et al., 
1998; Exley et al., 2011) and nicotine reward (Maskos et al., 2005; Tapper et al., 
2007; Pons et al., 2008; McGranahan et al., 2011).  However, various nAChR 
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nicotine reward is the result of manipulation of dopaminergic neuronal activity 
(Laviolette and van der Kooy, 2004).  Furthermore, studies in mice that lack the 
β2 nAChR subunit indicated nicotine acts upon β2* nAChRs on DAergic neurons 
to initiate burst firing activity and induce dopamine release (Picciotto et al., 
1998a; Mameli-Engvall et al., 2006).  Mice lacking the α4 nAChR exclusively in 
dopaminergic neurons failed to exhibit nicotine place preference but retained 
preference conditioned by cocaine (McGranahan et al., 2011).  Furthermore, re-
expression studies in mice lacking α4 nAChR demonstrated the α4 nAChR 
subunit is also necessary for burst firing activity  (Exley et al., 2011).  Nicotine 
activates DAergic neurons in the posterior VTA, specifically through α4* nAChRs, 
to induce reward (Ikemoto et al., 2006; Zhao-Shea et al., 2011).  Ethanol also 
leads to the activation of DAergic neurons through α4* nAChRs on pVTA 
DAergic neurons (Hendrickson et al., 2010). Nicotinic receptors containing the α6 
subunit on DAergic neurons remain activated by nicotine (Liu et al., 2012), while 
chronic nicotine leads to the upregulation of α6* nAChR in VTA DAergic neurons 
(Baker et al., 2013).  However, studies in mice that express hypersensitive α6 
nAChR subunits but lack α4 nAChR subunits indicate that α4 nAChRs are 
required for nicotine-mediated behaviors (Drenan et al., 2010).  In summary, it is 
hypothesized that nicotine acts upon VTA DAergic neurons through the α4α6β2* 
nAChR subtype to initiate its psychotropic effects (Figure I-4). 
Few studies have been done to examine how nAChRs affect VTA GABAergic 
activity.  In contrast with the VTA DAergic neurons, VTA GABAergic neurons 
express a discrete number of nAChRs subtypes: α3, α4, β2, α7 and possibly α6, 
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though this may be restricted to interneurons (Charpantier et al., 1998; Klink et 
al., 2001; Yang et al., 2011) (Figure I-4).  Electrophysiological studies have 
indicated that α4β2* nAChRs on GABAergic neurons of the VTA are desensitized 
with chronic nicotine exposure (Mansvelder and McGehee, 2002), which falls in 
line with the accepted ‘disinhibition’ hypothesis.   A recent study that rescued β2 
nAChR subunit expression in either DAergic or GABAergic VTA neurons 
suggests β2* nAChRs expression in VTA DAergic and GABAergic neurons 
shapes the burst-firing activity often observed in reward signaling (Tolu et al., 
2013), indicating that VTA GABAergic neurons may modulate nicotine reward 
signaling rather than solely restricting DAergic activity.  
 
I.D. Rodent models used to study nAChR subunits in the VTA 
Our understanding of the neurobiological contributions of nAChR subunits greatly 
benefited from rodents experiments implementing pharmacological reagents, 
genetic-engineered mice and viral-delivered strategies (Table I-1).  Studies 
discussed in this section will focus on nAChRs found within the VTA (Fig I-4), 
with particular emphasis on the α4 and β2 subunits, due to multiple studies 
indicating the importance of these subunits to the reinforcing and rewarding 
properties of nicotine.  
 
Pharmacology 
Pharmacological reagents have been used to assess nAChRs function on 
behavior.  Mecamylamine (Inversine), a non-selective and non-competitive 
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nAChR antagonist (Takayama et al., 1989),  has been used for more than twenty 
years to alter nAChR activity.  First prescribed as an antihypertensive, 
mecamylamine readily crosses the blood brain barrier to allosterically inhibit 
nAChR activation.  Administration of mecamylamine either through subcutaneous 
injection or infusion into the VTA reduced nicotine self-administration (Nisell et 
al., 1994; Watkins et al., 1999)  and diminished cue instated nicotine reward (Liu 
et al., 2007, 2010), confirming that nAChR activation is necessary for the 
rewarding and reinforcing properties of nicotine.  Mecamylamine precipitated 
withdrawal symptoms in chronically nicotine treated animals (Hildebrand et al., 
1999; Watkins et al., 2000), further implicating deactivation of nAChRs 
contributes to nicotine withdrawal syndrome.   Because different nAChR 
subtypes can have varying reactions to nicotine, it is important to take into 
account nAChR composition.  Dihydro-beta-erythrodine (DHβE) is a nAChR 
direct antagonist that is selective to α4* and α3β4* nAChRs (Damaj et al., 1995; 
Harvey et al., 1996).    Administering DHβE either systemically or intracranially 
prior to nicotine self-administration diminishes nicotine’s reinforcing effects 
(Corrigall et al., 1994; Watkins et al., 1999), further narrowing down the potential 
nAChR subtypes important for nicotine reward and reinforcement.  Receptor 
function can be inferred indirectly using drugs that inactivate certain nAChR 
subtypes.  Varenicline (Chantix), a partial agonist for α4β2* nAChRs as well as a 
full agonist for α7 nAChRs (Coe et al., 2005; Mihalak et al., 2006) reduced 
nicotine self-administration in rats (Rollema et al., 2007)  and alcohol reward in 
mice (Hendrickson et al., 2010).  
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important for nicotine dependence behaviors.  However, because these drugs 
target other nAChR subunits that are expressed within the VTA, these results 
leave open the possibility that other  receptor subtypes can also contribute.   
 
Genetically Engineered Mouse Strains  
The advent of rodent genetic engineering brought forth a whole new avenue for 
studying nAChR subtypes through genome modification.  Because the diversity 
of nAChR subtypes expressed throughout the brain and the lack of reagents that 
target a discrete nAChR subtype, the generation of animals lacking a particular 
nAChR subunit, or nAChR knock-out (KO) mice, provided a novel way to 
determine the physiological function of each nAChR subunit (Cordero-Erausquin 
et al., 2000; Zhang et al., 2006).  The nAChR KO mouse lines provide a way to 
access the physiological necessity of a nAChR subunit both in development and 
in behavior.  A nAChR mouse KO line exists for each mammalian nAChR 
subunit, with the addition of several double KO mouse lines (Table I-1).  Deletion 
of a subunit yielded obvious developmental phenotypes, as α3 nAChR KO mice 
failed to live pass 7 days and exhibited gross autonomic nervous system 
abnormalities, such as dialated pupils, extended bladders and poor bladder 
control (Xu et al., 1999a). Interestingly, mice lacking both the β2 and β4 subunit 
were non-viable and exhibited a similar fate to the α3 KO mouse line (Xu et al., 
1999b), hinting at compensatory mechanism between beta nAChR subunits, as 
the single nAChR KO mice are viable (Picciotto et al., 1998a; Xu et al., 1999b).   
Development of KO mice also identified the function of the subunit within a 
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system, such as the α9 and α10 nAChR subunits (Vetter et al., 1999; 
2007)(Table I-1). Other nAChR KO mice were viable, providing a stable system 
to further determine the role of the subunit in basic behavior and with nicotine 
exposure (Cordero-Erausquin et al., 2000).  Mice from the α7 KO line still 
consumed nicotine, which suggests that α7 nAChRs are not necessary for 
nicotine reward (Pons et al., 2008).  Mice lacking the β2 nAChR self-
administered nicotine significantly less than control mice and midbrain 
dopaminergic neurons in these mice failed to respond to nicotine (Picciotto et al., 
1998).  This study confirmed the importance of the β2 nAChR subunit in the 
rewarding and reinforcing effects of nicotine.  The β2 nAChR subunit is 
expressed in 90% of the brain and is commonly co-expressed with the α4 nAChR 
subunit (Perry et al., 2002; Gotti et al., 2009).   Other studies into nAChR KO 
mice have implicated the necessity of the α4 and the α6 nAChR subunits in 
nicotine-mediated dopamine transmission (Marubio et al., 2003; Liu et al., 2012), 
while α7 nAChR KO did not exhibit rapidly desensitizing nicotine currents (Orr-
Urterger et al., 1997).   Mouse strains lacking the β2, α4 and α6 nAChR subunit 
fail to self-administer nicotine, further indicating the role of these receptors in 
mediating nicotine reward (Maskos et al., 2005; Pons et al., 2008; Exley et al., 
2011).  Together, nAChR KO mice provided much insight into the necessity of 
each nAChR subunit in regards to overall development and physiological 
function.  However, developmental issues due to the lack of a particular nAChR 
subunit may result in differences in adult behavior that do not reflect physiological 
conditions (Picciotto, 1998b; Muller, 1999; Changeux and Champtiaux 2004).  
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Furthermore, KO models do not assess if a nAChR is sufficient to drive a 
particular behavior.  
To address the question of sufficiency, genetically engineered mice expressing 
nAChR subunits harboring a point mutation at the 9´ leucine of the TM2 domain 
were generated.  As previously described, this mutation conferred “gain-of-
function” nAChRs in vitro (Revah et al., 1991; Labarca et al., 1995).  
Hypersensitive nAChR mice provided a novel method to preferrentially activate 
nAChRs containing the mutated nAChR subunit and observe the effects on firing 
frequency, neurotransmitter release and ultimately behavior.  Currently, mice 
expressing “gain-of-function” α4, α6, α7 or α9 nAChR subunits are available 
(Drenan and Lester, 2012) (Table I-1).  The majority of these mice were 
generated through homologous recombination (Orr-Urtreger et al., 2000; Labarca 
et al., 2001; Tapper et al., 2004; Taranda et al., 2009), with the exception of the 
α6 Leu9´Ser mouse line that utilized a bacterial artificial chromosome to express 
α6 Leu9´Ser nAChR subunits (Drenan et al., 2008).  Selectively activating α4* 
nAChRs using mice expressing α4* nAChRs containing a leucine to alanine point 
mutation at the 9´ residue at TM2 (Leu9´Ala) conferred Conditioned Place 
Preference with a sub-threshold dose of nicotine (Tapper et al., 2004),  
confirming that α4* nAChRs are sufficient to elicit nicotine reward. However, one 
study utilizing a mouse line harboring an α4 nAChR mutation found in patients 
with autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE) suggested 
the α4 nAChR is critical in the hypolocomotor properties of nicotine, but only 
plays a modulatory role in nicotine reinforcement (Cahir et al., 2011).  Other 
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knock-in mouse line harboring a leucine to serine 9´ mutation on the α4 nAChR 
TM2 (Leu9´Ser) had elevated anxiety-like behavior and altered hippocampal 
theta rhythms (Fonck et al., 2003).  This suggests that α4* nAChR may also be 
involved in nicotine withdrawal syndrome.  Mice expressing α6 Leu9´Ser nAChR 
mice have also been bred to α4 KO mice to determine the sufficiency of α6* 
nAChR receptors in the absence of the α4 nAChR subunit.  This study showed 
that α4 nAChR expression is necessary for the behavioral effects observed in α6 
Leu9´Ser nAChR mice (Drennan et al., 2010).  Despite the power of the 
technique, expression of hypersensitive mutant nAChR subunits also resulted in 
heightened mortality in homozygous mice expressing either mutant α4 or α7 
nAChR subunits (Orr-Urtreger et al., 2000; Labarca et al., 2001).  In vitro studies 
have observed differences in receptor dynamics in the mutant subunits, such as 
the slowing of desensitization rates (Revah et al., 1995) and increasing of 
receptor opening time (Labarca et al., 1999).  How this is translated to neuronal 
activity in in vivo models has not been thoroughly investigated.  Overall, mice 
expressing hypersensitive nAChRs provide a “gain-of-function” assessment of 
nAChR subunits that compliments the “loss-of-function” studies, by providing 
context into the sufficiency of the nAChR subunit in nicotine-mediated behaviors.   
Although KO mice address the issue of necessity and the hypersensitive mice 
addresses the issues of sufficiency, nAChRs are expressed in various brain 
regions (Gotti and Clementi, 2004; Changeux 2010; Pistillo et al., 2014).  Neither 
KO mice nor hypersensitive nAChR mice provide a way to assess how a 
particular nAChR receptor affects a specific brain region.  To address this 
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question, lentiviral-mediated nAChR expression systems were developed to 
rescue nAChR subunit expression in specific brain areas of KO mice.  Results of 
these studies further highlighted the importance of nAChR expression within the 
region and the sufficiency of the region to mediate behavior.  The first of these 
experiments rescued the expression of β2 nAChR subunits in the VTA of β2 KO 
mice, which resulted in the reinstatement of nicotine self-administration (Maskos 
et al., 2005). Re-expressing α4 and α6 nAChRs specifically within the VTA and 
β2 nAChRs within the VTA and substantia nigra led to similar results (Pons et al., 
2008).  Further studies of selective re-expression of α4* nAChRs in the VTA 
rescued intracranial self-administration and restored nicotine-induced burst firing 
activity in VTA DAergic neurons (Exley et al., 2011).  Together, these data further 
implicate the necessity of high-affinity nAChRs, particularly α4* nAChRs within 
the VTA as important for nicotine consumption.  However, viral particles can 
infect multiple cellular populations within the brain, including nearby astrocytes.  
Therefore, it is difficult to conclude the re-expression of the nAChR subunit 
specifically addresses DAergic neuronal activity when astrocytes, DAergic and 
GABAergic neurons are all present.  Furthermore, the lack of restricting 
expression to a specific cell population can lead to the formation of non-
physiological nAChRs.  To understand the contributions of high-affinity nicotinic 
receptors within the subpopulations of the VTA, Tolu and colleagues (2102) 
utilized a Cre-restricted lentiviral expression system to selectively re-express β2 
nAChRs in DAT-expressing or GAD-expressing neurons.  These studies found 
that expression of high-affinity nicotinic receptor are necessary on both DAergic 
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and GABAergic neurons to shape the burst firing of DAergic neurons (Tolu et al., 
2012), providing insight into how high-affinity nAChRs on GABAergic neurons 
affect DAergic activity.  Furthermore, re-expressing α5 nAChR subunits 
containing a mutation commonly associated with smokers in the VTA resulted in 
increased consumption and decreased activation of VTA DAergic neurons by 
nicotine (Morel et al., 2013).  Decreased DAergic neuron activation was observed 
to promote drug seeking, which can explain sustained nicotine use (Epping-
Jordan et al., 1999).  Lentiviral-mediated gene expression provides precision in 
determining the necessity of nAChR subunit expression within a particular brain 
region, but is dependent on KO mice.  Therefore, developmental issues from 
compensatory mechanisms potentially confound the results.  The lentiviral vector 
integrates the gene of interest randomly into the genome, which increases the 
susceptibility of the target gene to various genome silencing mechanisms.  
Furthermore, high protein expression is achieved by a high concentration of viral 
particles; therefore, high viral titers are necessary for sufficient expression. An 
alternative viral vector recently gaining favor is the adeno associate virus (AAV).  
Unlike lentiviruses, AAV genomes form an episome upon entry into the cell 
instead of integrating into the host genome, therefore bypassing gene silencing 
through methylation and unwanted complications due to insertional mutagenesis 
(Davidson et al., 2011).  Furthermore, AAV is considered Risk Group 1 agent and 
can be use without additional accomodations or special facilities.  High AAV viral 
titers are also easier to achieve compared to lentivirus, further increasing the 
chances for robust gene expression.  AAV has been used to reconstitute gene 
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expression in rodent models of neurological disorders, such as Canavan’s, 
Parkinson’s and Alzheimer’sDisease (McPhee et al., 2004; Cederfjäll et al., 2012; 
Fol et al., 2015).  In addition, the viral vector has been used to deliver genes in a 
Cre-dependent manner without any complications (Atasoy et al., 2008).  
Regardless, these previous studies further reinforce the idea that α4* nAChRs 
are crucial for nicotine reward. 
It is unclear how nAChR upregulation contributes to the development of nicotine 
dependence.  Several studies assessed how withdrawing from nicotine affected 
the reinforcing responses of the drug.  Mice chronically treated with nicotine 
exhibited a stronger place preference when repeatedly withdrawn from nicotine, 
and repeated exposures of nicotine led to the upregulation of high-affinity 
nAChRs (Hilario et al., 2012). Whether these upregulated nAChRs play an active 
role in initiating these behaviors is unknown.  Upregulation of nicotinic receptors, 
in particular high affinity nAChRs, occurs in distinct parts of the brain (Marks et 
al., 1983; Nashmi et al., 2007; Muhkin et al., 2008; Hilario et al., 2012).  Chronic 
nicotine exposure results in the upregulation of functional α4* nAChRs in VTA 
GABAergic neurons (Nashmi et al., 2007, Renda and Nashmi, 2014).  A recent 
study observed that α4* nAChRs were upregulated with chronic nicotine 
treatment, which was correlated with increased consumption of nicotine-laced 
water (Renda and Nashmi, 2014).  This is in contrast with optogenetic studies 
indicating VTA GABAergic activation elicits aversion (Tan et al., 2012; Van 
Zessen et al., 2012; Cohen et al., 2012).  However, unlike optogenetic 
stimulation, nAChR activation is thought to be more modulatory than stimulatory 
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(Picciotto, 2003).  Furthermore, high-affinity nicotinic receptors on both VTA 
dopaminergic and GABAergic neurons are necessary to shape the burst firing 
activity of DAergic neurons associated with reward signaling (Tolu et al., 2013),  
indicating that nAChR activation on VTA GABAergic neurons does not 
necessarily elicit aversion.  Interestingly, ex-smokers exhibit an increase in 
GABAA receptors in areas involved in nicotine reward (Stokes et al., 2013),  
which is hypothesized to be due to a compensatory mechanism for the lack of 
GABA released during smoking.  Many of these regions also receive GABAergic 
projections from the VTA, such as the NAc (Taylor et al., 2014).  It is quite 
possible that directly activating VTA GABAergic neurons through nicotine can 
affect these regions to promote nicotine dependence, seeing that these regions 
are heavily implicated with reward and associative learning (Brown et al., 2012).  
 
I.E. The Habenula, Interpeduncular Nucleus and Nicotine Withdrawal 
The role of stress in drug abuse is well established and heavily implicated in 
increasing craving and promoting relapse (Sinha, 2008; 2009).  Stressful stimuli 
can increase negative affective symptoms, as stressed smokers withdrawn from 
nicotine exhibited heightened negative affect (McKee et al., 2011).  The release 
of CRF increased anxiety-like behavior through the VTA to instigate drug relapse 
(Wise, 2010).  Footshock induced CRF transmission within the VTA in both 
cocaine naïve and cocaine exposed rodents, indicating that CRF release was 
dependent only on stressful stimuli (Wang et al., 2005). CRF release into the 
VTA can originate from various regions as well as occur locally. Chronic nicotine 
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exposure led to increased CRF transcript expression in VTA DAergic neurons, 
while infusing CRF1 receptor antagonists in the pVTA of nicotine withdrawn mice 
abolished aversion (Grieder et al., 2014), implicating a potential role of the pVTA 
in nicotine withdrawal symptoms.  Another study silenced CRF production in the 
VTA and observed decreased activation of the IPN and decreased anxiety, 
highlighting a possible VTA to IPN pathway that nicotine induces withdrawal 
symptoms and potentially be involved in signaling stress (Zhao-Shea et al., 
2014).   
There has been a recent surge of interest in the habenula and the IPN in regards 
to nicotine withdrawal. The habenula is a small symmetrical brain region 
surrounded by the third ventricle and located dorsal to the posterior thalamus.  It 
is further portioned into medial (MHb) and lateral (LHb) subnuclei due to 
differences in cytostructure and genetic profile.  The LHb is involved in negative 
reward signaling and indirectly inhibits the VTA via the RMTg while the MHb is 
implicated in anxiety and nicotine withdrawal.  Furthermore, the MHb is further 
organized into subsections based on neuronal subpopulation and projection 
targets.  The MHb contains a high concentration as well as a wide range of 
nAChR subunits, many associated with aversive nicotine withdrawal symptoms 
(Connolly et al., 1995; Quick et al., 1999; Salas et al., 2004; 2009; Viswanath et 
al., 2014).   
The IPN is a midbrain region situated along the midline and ventral to the VTA.  It 
is comprised of 4 paired and 3 unpaired subnuclei.  Neurons within the IPN 
express glutamate decarboxylase, the enzyme that catalyzes GABA; therefore, 
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the neurons within the IPN are thought to be mostly GABAergic (Kawaja et al., 
1989; Zhao-Shea et al., 2013).  Like the MHb, the IPN also expresses nAChR 
subunits associated with nicotine withdrawal (Salas et al., 2004; 2009; Velasquez 
et al., 2014).  Optical activation of GABAergic neurons within the IPN induces 
somatic stereotypical withdrawal behaviors in chronic nicotine treated mice, 
suggesting the IPN is involved in the expression of withdrawal symptoms.  
Additionally, blockage of β4 nAChRs within the IPN leads to increased instances 
of somatic symptoms (Zhao-Shea et al., 2015).    The IPN also contains CRF1 
receptors possibly innervated by CRF produced in the VTA (Greider et al., 2014; 
Zhao-Shea et al., 2015).   
The majority of the projections from the MHb innervate the IPN via the fasiculus 
retroflexus. The IPN receives projections from the MHb in a topographical 
manner; that is, nuclei situated in the midline receive innervation from the ventral 
MHb, a region consisting of ChAT-expressing neurons. Optogenetic studies 
demonstrated that the neurons in the MHb release both acetylcholine and 
glutamate, depending on the frequency of stimulation (Ren et al., 2011). These 
data suggest the MHb-IPN circuit could possibly works in opposition to the 
mesocorticolimbic pathway to reduce reward and promote withdrawal symptoms 
in order to maintain nicotine dependence (Koob and Volkow, 2008). 
 Nicotine withdrawal can be instigated in the laboratory setting by either 
withdrawing a mouse from the source of nicotine for 24 hours or administering a 
nicotinic receptor antagonist (Damaj et al., 2003; Salas et al., 2004., Salas et al., 
2009). An injection of either DHβE, mecamylamine or MLA to nicotine-adapted 
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rodents induced somatic withdrawal symptoms (Hildebrand et al.,1997, Epping-
Jordan et a., 1998, Damaj et al., 2003).  The specificity of these nicotinic receptor 
antagonists suggests nAChRs containing the α3, α4, β2 and α7 nAChR subunits 
are involved in nicotine withdrawal.  Infusion of mecamylamine into the VTA was 
sufficient to precipitate somatic withdrawal symptoms (Hildebrand et al., 1997), 
suggesting that the VTA as a candidate region involved in nicotine withdrawal.  
However, it is possible that mecamylamine also affected nAChRs within the IPN, 
due to the proximity of the nucleus to the VTA.   
Although not as extensively studied as nicotine reward, nAChRs located within 
the MHb and the IPN have been linked to behaviors involved in nicotine 
dependence.  A series of studies have screened each nAChR KO line and 
concluded that the subunits implicated in somatic symptoms of nicotine 
withdrawal were α2, α5, β4 but not α7 or β2 (Salas et al., 2004, 2009; Jackson et 
al., 2012).  The α2, α5, β4 nAChR subunits are extensively expressed in the 
MHb and the IPN.  Mice lacking the α2, α5 or β4 nAChRs failed to exhibit 
nicotine withdrawal symptoms while α7 and β2 KO mice exhibited withdrawal 
symptoms when given MLA or mecamylamine, respectively (Salas et al., 2004, 
2009).  Viral-mediated re-expression studies further implicated the brain regions 
involved in nicotine consumption.  Intravenous self-administration studies found 
that α5 KO mice administered nicotine readily at high doses, and reinstating α5 
nAChR subunits in the MHb lowered the preferred dose  (Fowler et al., 2011).  
The authors proposed α5 nAChRs within the MHb are involved in an inhibitory 
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circuit that restricts continued nicotine consumption.  Dysregulation of this circuit 
could instigate behaviors involved in nicotine withdrawal.    
 
I.F. Thesis Overview 
The overall goal of the work described within this thesis is to understand the 
impact of nicotinic acetylcholine receptor “upregulation”- a well-characterized 
neuroadaptation that occurs with chronic nicotine consumption- on a classical 
pathway involved in nicotine-mediated behaviors.  I developed a gene expression 
system in order to mimic the upregulation of α4* nAChRs.  This gene expression 
system conferred α4 nAChR subunits with a 9´ leucine to serine point mutation 
(Leu9´Ser) in a Cre-restricted manner to generate “gain-of-function” α4* nAChRs 
in discrete neuronal subpopulations.   This experimental design allows to 
distinguish the contribution of “upregulated” α4* nAChR from baseline α4* 
nAChR, as well as discern the impact of activation of VTA GABAergic α4* 
nAChRs on nicotine dependence behaviors.  Expression and function of viable 
Leu9´Ser α4* nAChRs was verified through immunohistochemical and 
electrophysiological techniques.  Furthermore, expressing these Leu9´Ser α4* 
nAChRs did not change locomotor activity or induce anxiety.  Finally, expression 
of Leu9´Ser α4* nAChRs in VTA GABAergic neurons increased sensitivity to 
nicotine reward.   
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CHAPTER II. 
FUNCTIONAL UPREGULATION OF α4* NICOTINIC ACETYLCHOLINE 
RECEPTORS IN VTA GABAERGIC NEURONS INCREASES SENSITIVITY TO 
NICOTINE REWARD 
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ABSTRACT 
Chronic nicotine exposure increases sensitivity to nicotine reward during a 
withdrawal period which may facilitate relapse in abstinent smokers, yet the 
molecular neuroadaptation(s) that contribute to this phenomenon are unknown.  
Interestingly, chronic nicotine use induces functional upregulation of nicotinic 
acetylcholine receptors (nAChRs) in the mesocorticolimbic reward pathway 
potentially linking upregulation to increased drug sensitivity.  In the ventral 
tegmental area (VTA) functional upregulation of nAChRs containing the a4 
subunit (α4* nAChRs) is restricted to GABAergic neurons.  To test the hypothesis 
that increased functional expression of α4* nAChRs in these neurons modulates 
nicotine reward behaviors, we engineered a Cre recombinase-dependent gene 
expression system to selectively express α4 nAChR subunits harboring a “gain-
of-function” mutation (a leucine mutated to a serine residue at the 9´ position: 
Leu9´Ser) in VTA GABAergic neurons of adult mice.  In mice expressing 
Leu9´Ser α4 nAChR subunits in VTA GABAergic neurons (Gad2VTA: Leu9´Ser 
mice), sub-reward threshold doses of nicotine were sufficient to selectively 
activate VTA GABAergic neurons and elicit acute hypolocomotion which 
developed tolerance with subsequent nicotine exposures compared to control 
animals.  In the conditioned place preference procedure, nicotine was sufficient 
to condition a significant place preference in Gad2VTA: Leu9´Ser mice at low 
nicotine doses that failed to condition control animals.  Together, these data 
indicate that functional upregulation of α4* nAChRs in VTA GABAergic neurons 
confers increased sensitivity to nicotine reward and points to nAChR subtypes 
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specifically expressed in GABAergic VTA neurons as molecular targets for 
smoking cessation therapeutics. 
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INTRODUCTION 
Chronic exposure to tobacco smoke accounts for ~5 million deaths per year 
making health complications from smoking the primary cause of preventable 
mortality in the world (Harris and Anthenelli, 2005).  Nicotine, the addictive 
component of tobacco, binds to and activates neuronal nicotinic acetylcholine 
receptors (nAChRs), ligand-gated cation channels that are normally activated by 
the endogenous neurotransmitter, acetylcholine (ACh).  Nicotine initiates 
dependence by activating neurons within the ventral tegmental area (VTA) of the 
mesocorticolimbic reward circuitry, ultimately driving the release of dopamine 
(DA) within the nucleus accumbens (NAc), a phenomenon widely associated with 
the rewarding or reinforcing value of nicotine (De Biasi and Dani, 2011).  A large 
variety of nAChR subunit genes are expressed in both VTA DAergic projection 
neurons and GABAergic neurons (Klink et al., 2001, Wooltorton et al., 2003). 
Neuronal nAChRs are pentameric receptors consisting of homologous or 
heterologous combinations of subunits.  Twelve genes encoding twelve individual 
nAChR subunits have been identified, accounting for a vast array of nAChR 
subtypes each with distinct pharmacological and biophysical properties.  A great 
deal of effort has focused on identifying nAChR subtype expression within the 
VTA to determine which subtypes, when activated, are necessary and sufficient 
for nicotine reinforcement and/or reward (Picciotto et al., 1998, Tapper et al., 
2004, Maskos et al., 2005, Pons et al., 2008).  From these studies, a general 
consensus is that expression of nAChRs containing α4 and β2 subunits in the 
VTA are both necessary and sufficient for nicotine reinforcement with at least 
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some contribution of the α6 subunit (Pons et al., 2008, Brunzell et al., 2010, Gotti 
et al., 2010).  However, α4 and β2 subunits are expressed in both VTA DAergic 
neurons and GABAergic neurons (Klink et al., 2001, Wooltorton et al., 2003).  
While nicotine can directly activate VTA DAergic neurons, recent studies suggest 
that activation of GABAergic neurons may also modulate DAergic neuron activity 
and is required for nicotine reinforcement (Tolu et al., 2012). 
Unlike other drugs of abuse, chronic use of nicotine leads to increased 
expression or “upregulation” of α4β2* nAChRs (“*” denotes that nAChR subunits 
in addition to α4 and β2 may be assembled in the nAChR complex) in the 
mesocorticolimbic pathways in addition to other brain regions.  While 
upregulation of nAChRs is a hallmark of chronic nicotine exposure, the 
behavioral consequence of this phenomenon and how it relates to nicotine 
dependence is unknown (Wonnacott, 1990).  Interestingly, functional 
upregulation of α4* nAChRs in the mesolimbic pathway appears to be restricted 
to midbrain GABAergic neurons including those of the VTA (Nashmi et al., 2007, 
Xiao et al., 2009).  In addition, the rewarding properties of nicotine have been 
shown to increase in chronic nicotine-exposed mice, perhaps linking upregulation 
and increased functional α4* nAChR expression in VTA GABAergic neurons with 
reward behavior (Hilario et al., 2012).  We sought to test the hypothesis that 
increased functional expression of α4* nAChRs selectively in VTA GABAergic 
neurons will increase sensitivity to nicotine reward. 
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MATERIALS AND METHODS 
 
Mice.  C57BL/6J and Gad2-Cre (strain B6N.Cg-Gad2tmz(cre)Zhj/J) male mice on a 
C57BL/6J background were used in this study (Jackson Lab, Bar Harbor, ME, 
USA)(Taniguchi et al., 2011).  Adult (8 to 10 weeks old) Gad2-Cre mice were 
injected with viral particles and used for behavioral experiments 4-6 weeks post-
infection.  All mice were kept on a 12-hour light-dark cycle with lights on at 0700 
hours and off at 1900 hours.  All mice were given food and water ad libitum.  All 
procedures were performed in compliance with the Institutional Animal Care and 
Use Committee of the University of Massachusetts Medical School. 
 
Drugs.  For acute treatments, nicotine hydrogen tartrate, mecamylamine 
hydrocholoride (Sigma-Aldrich, St. Louis, MO, USA) and dihydro-β-erythroidine 
hydrobromide (DHβE, Tocris Bioscience, Bristol, UK) were dissolved in sterile 
0.9% phosphate buffered saline (PBS) (Hospira, Lake Forest, IL, USA).  Nicotine 
was titrated to physiological pH (7.4) before being administered to mice.  Vials 
containing nicotine solutions were wrapped in aluminum foil to prevent 
degradation by light exposure.  For chronic exposure studies, nicotine dihydrate 
ditartrate (200 µg/ml, Acros Organics, Geel, Belgium) and L-tartaric acid (300 
µg/ml, Sigma-Aldrich) were dissolved in water.  Saccharin sodium (3 mg/ml, 
Fisher Scientific) was added to both solutions to increase palatability.  Doses for 
nicotine, mecamylamine, and DHβE were calculated as free base.  All injections 
were administered subcutaneously (s.c.). 
 
 46 
Viral Plasmid Engineering.  The mouse α4-YFP nAChR subunit cDNA was 
obtained from Addgene (plasmid 15245) and has been described previously 
(Nashmi 2003).  Using the Quickchange Site-Directed Mutagenesis Kit (Agilent 
Technologies, Santa Clara, CA, USA), PCR mutagenesis was done to convert 
the 9´ leucine of the M2 pore domain to a serine (changing the codon from CTT 
to TCT).  The resulting construct contained an α4-YFP cDNA with the leucine to 
serine mutation (Leu9´Ser α4-YFP).  The Leu9´Ser α4-YFP cDNA was sub-
cloned into the AAV expression vector pAAV-EF1a-DIO-WPRE-pA (Tsai et al., 
2009).   
 
Chronic Nicotine Exposure.  Animals were restricted to drinking either control 
(tartaric acid, 300 µg/ml and 3 mg/ml saccharin) or nicotine- (200 µg/ml and 3 
mg/ml saccharin) treated water through a 250-ml opaque water bottle placed in 
the home cage for 6-8 weeks.  To induce withdrawal, the nicotine bottle was 
replaced with a water bottle (Zhao-Shea et al., 2013). 
 
Viral-Mediated Gene Delivery.  Both the pAAV-EF1a-Leu9Ser-a4-YFP (Leu9´Ser 
α4-YFP) and pAAV-EF1a-DIO-hChR2(H134R)-EYFP-WPRE-pA (control) 
constructs were packaged into AAV2 viral particles by the University of 
Massachusetts Medical School Viral Vector Core.  Viral titers were 1012 viral 
particles/µl with 1 µl of viral supernatant bilaterally injected into the VTA.  Gad2-
Cre animals were anesthetized with ketamine/xylazine (0.1 ml/10g body weight, 
10 mg/ml ketamine, 1 mg/ml xylazine).  To prep the surgical area, fur was 
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shaved and skin was disinfected with 10% povidone-iodine.  The VTA was 
located with a stereotaxic frame (Stoelting, Wood Dale, IL, USA) using the 
following coordinates from bregma: -3.3(AP), +/- 0.3 (ML), -4.0 (DV).  Viral 
particles were infused into the brain using an injection syringe (Hamilton, Reno, 
NV, USA) attached to a syringe pump (Stoelting Quintessential Stereotaxic 
Injector, Stoelting) at a rate of 0.25 ml/min.  The injection needle was left in place 
for 10 min after each injection and then slowly retracted.  Mice were given 5% 
glucose and 15 mg/kg ketaprofen after fully regaining consciousness.  Mice were 
given four weeks for recovery and to allow for expression of the viral particles 
prior to each experiment. 
 
Immunofluorescence.  For c-Fos immunolabeling, animals received s.c. saline 
injections three days prior to each experiment to reduce possible effects of stress 
and/or handling on neuronal activity.  To assess c-Fos expression, Gad2-Cre 
male mice infected with either control or Leu9´Ser α4-YFP were injected either 
with saline or 0.09 mg/kg nicotine.  Ninety minutes after drug administration, 
brains were harvested for slice preparation.  Animals were anesthetized with 200 
mg/kg sodium pentobarbital (interperitoneal injection) and transcardiacally 
infused with 10 ml of chilled 0.1 M PBS following with chilled 4% (w/v) 
paraformaldehyde dissolved in 0.1 M PBS.  The brains were harvested and 
placed in cold 4% paraformaldehyde for 2 h before submerging in 30% sucrose.  
Brains were then sectioned into 30-mm slices using a microtome (Leica, Buffalo 
Grove, IL, USA) and immunolabeled via free-floating sections.  Slices were 
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washed in PBS for 5 min, permeabilized in 0.2% (v/v) Triton-X (Sigma-Aldrich) 
for 5 min, and blocked with 2% Bovine Serum Albumin (BSA) (Fisher Scientific, 
Waltham, MA, USA) for 30 min before incubation with primary antibody in 2% 
BSA overnight at 4 C°.  Primary antibodies used were:  mouse anti-TH MAB318 
(1:1000, lot number: 2499557, Millipore, Billerica, MA, USA), rabbit anti-Gad1/2 
(1:2000, lot number: 122M4761, Sigma-Aldrich), rabbit anti-c-Fos (1:1000, lot 
number: F2510, Santa Cruz, Santa Cruz, CA, USA), rabbit anti-GFP (1:4000, lot 
number: GR158277-1, Abcam, Cambridge, MA, USA), mouse anti-calbindin 
(1:3000, lot number: 052M4833, Sigma-Aldrich), rabbit anti-calretinin (1:1000, lot 
number: AB5054, Millipore), rabbit anti-parvalbumin (1:1000, lot number: 
ab11427, Abcam) and goat anti-somatostatin (1:100, lot number: sc-789, Santa 
Cruz).  Secondary antibodies were Alexa Fluor 405 (lot number: 1126599), 488 
(lot number: 1608521) and 594 (lot numbers: 1431805, 1003216 and 1602780) 
(1:1000, Life Technologies, Grand Island, NY, USA).  An AxioCam MRm camera 
(Carl Zeiss Microscopy GmbH, Jena, Germany) attached to a Zeiss Axiovert 
inverted fluorescent microscope equipped with Zeiss filter sets 38HE, 49, and 20 
was used to acquire fluorescent images.  Zeiss objectives A-plan 10x, EC-Plan-
NEOFLUAR 20x and Plan-APOCHROMAT-63x were used to view and capture 
images.  Images were processed using Axiovision v.4.8.2.  For quantification and 
co-localization analysis, images were deconvoluted and segmented using the 
segmentation and quantification of subcellular shapes (Squassh) software plugin 
through ImageJ.  At least 10 slices/mouse brain that spanned the entire VTA 
were analyzed.  The VTA was located using TH staining and morphology of 
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nearby brain regions as previously described (Zhao-Shea et al., 2011).  Areas of 
interest for each slice were identified through TH fluorescence and measured in 
ImageJ using the “Analyze Particles” option to account for differences between 
slices. 
 
Electrophysiological Recordings.  Mice were deeply anesthetized with sodium 
pentobarbital (200 mg/kg, i.p.) and then decapitated.  Slices were prepared as 
previously described (Zhao-Shea et al., 2011).  Briefly, brains were quickly 
removed and placed in an oxygenated ice-cold high sucrose artificial 
cerebrospinal fluid (SACSF) containing kynurenic acid (1 mM, Sigma-Aldrich).  
Brain slices (180 - 200 µm) were cut using a Leica VT1200 vibratome (Leica 
Microsystem Inc.).  The brain slices were incubated in oxygenated Earl’s 
balanced salt solution (EBSS) supplemented with glutathione (1.5 mg/ml, 
Sigma), N-ω-nitro-L-arginine methyl ester hydrochloride (2.2 mg/ml, Sigma), 
pyruvic acid (11 mg/ml, Sigma) and kynurenic acid (1 mM) for 45 min at 34°C.  
Slices were transferred into oxygenated ACSF at room temperature for 
recording.  SACSF solution contained (in mM):  250 sucrose, 2.5 KCl, 1.2 
NaH2PO4•H2O, 1.2 MgCl2•6H2O, 2.4 CaCl2•2H2O, 26 NaHCO3, 11 D-Glucose.  
Single slices were transferred into a recording chamber continually superfused 
with oxygenated ACSF.  The junction potential between the patch pipette and 
bath ACSF was nullified just prior to obtaining a seal on the neuronal membrane.  
Action potentials and currents were recorded at 32°C using the whole-cell 
configuration of a Multiclamp 700B patch-clamp amplifier (Molecular Devices).  
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Action potentials measured in cell-attached mode were recorded at 31-32 ºC.  
Action potentials were obtained using a gap-free acquisition mode and Clampex 
software (Molecular Devices).  Ih currents were elicited every 5 sec by stepping 
from -60 mV to a test potential of -120 mV for 1 sec using Clampex.  Input 
resistances were calculated using steady state currents elicited by 5 mV 
hyperpolarizing pulses.  Signals were filtered at 1 kHz using the amplifier's four-
pole, low-pass Bessel filter, digitized at 10 kHz with an Axon Digidata 1440A 
interface and stored on a personal computer.  Potential VTA GABAergic neurons 
were selected for recording based on fluorescent signal and further verified by 
action potential frequency (~10-20 Hz) and lack of Ih expression.  At the end of 
recording, the neuronal cytoplasm was aspirated into the recording pipette and 
the contents were expelled into a microcentrifuge tube containing 75% ice-cold 
ethanol and stored at -20°C for at least 2 h before single-cell RT-PCR 
experiments to verify expression of GAD 1 and 2.  ACh chloride (Sigma) was 
dissolved in ACSF.  Whole cell ACh responses were recorded in the presence of 
TTX (0.5 mM), atropine (1 mM), bicuculline (20 mM), and CNQX (10 mM).  Drugs 
were applied to slices by gravity superfusion. 
 
Nicotine Tolerance.  Mice received s.c. saline injections three days before testing 
to habituate to handling.  Locomotor activity was recorded as beam breaks using 
the Photobeam Activity System (PAS) (San Diego Instruments, San Diego, CA, 
USA).  To determine baseline activity, mice were injected with saline and 
immediately placed into a novel cage inside the PAS locomotor chamber.  
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Activity was quantified for 15 min before mice were returned to their home cage.  
On the second day, mice received an s.c. injection of nicotine and immediately 
placed into a novel cage within the locomotor activity chamber.  Activity was 
measured for 15 min.  Mice were subsequently injected with nicotine each day 
for six more days, with locomotor activity recorded on the fourth and seventh day 
of nicotine challenge. 
 
Conditioned Place Preference.  A three-chamber conditioned place preference 
(CPP) apparatus (Med Associates, St. Albans, VT) was used to measure nicotine 
reward.  Briefly, at least three days prior to testing, mice were habituated to the 
test room and handling by picking them up once a day by the scruff of their neck.  
The testing protocol was comprised of three phases.  In the pre-training phase, 
mice were placed into the CPP apparatus and allowed to freely explore all three 
chambers for 15 min.  Time spent in each chamber was quantified using MEDPC 
IV software (Med Associates).  The training phase lasted four days, where each 
day the mice was twice confined to a chamber for 30 min.  In the morning 
session, mice were given an s.c. injection of sterile saline and placed in the 
chamber assigned as the saline-paired chamber.  Five hours later, mice were 
given an s.c. injection of drug (i.e. nicotine) and placed in the opposite, drug-
paired chamber.  The training phase was counterbalanced for each group in that 
approximately half the number of animals received nicotine paired with the white 
chamber while the other half received nicotine paired with the black chamber.  
Drug was paired with the least preferred chamber.  Mice that spent greater than 
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70 % of pre-training in any one chamber were not included in the analysis.  The 
post-training phase was identical to the pre-training phase.  Difference scores 
were measured by calculating the difference between the time spent in a 
chamber during the post-training phase and during the pre-training phase.  For 
CPP experiments testing nicotine reward in control and Leu9´Ser α4-YFP-
infected mice (as described below in Fig. 3 and Table 1), the CPP procedure was 
initiated 4-6 weeks post-infection.  Mice received saline in both chambers, 0.09 
mg/kg nicotine, or 0.5 mg/kg nicotine (n = 8-10 mice/group) during training.  
Additional groups of control and Leu9´Ser α4-YFP-infected mice were tested for 
CPP to 1 mg/kg mecamylamine (n = 8-10 mice/group), or 0.5/2.0 mg/kg DHβE (n 
= 6-8 mice/group) as described below in Fig. 4 A-B and Table 1.  For this set of 
experiments, CPP was performed exactly as described above except instead of 
nicotine during training, mice received mecamylamine or DHβE at the indicated 
dose.  For CPP in nicotine-dependent mice (Fig. 3C, inset and Table 1), mice 
were exposed to nicotine in their drinking water for 8 weeks.  Water bottles were 
swapped for untreated drinking water after the completion of the CPP pre-training 
phase and CPP was performed as above using 0.5 mg/kg nicotine during training 
(n = 11).  An additional group of control nicotine-naïve animals were also tested 
in the CPP procedure using 0.5 mg/kg nicotine (n = 11).    
 
Statistics.  Normality of data were tested prior to analysis.  Locomotor activity 
data were analyzed using repeated measure one-way analysis of variance 
(ANOVA).  CPP data were analyzed using two-way ANOVA with drug dose and 
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paired-chamber as main factors followed by Bonferroni post-hoc analysis as 
indicated.  c-Fos data were analyzed using two-way ANOVA with virus and drug 
treatment or neuron sub-type as main factors as indicated.  Fold-change 
differences in inward current were analyzed used a two-tailed t-test.  Data were 
analyzed using GraphPad Prism (GraphPad Software, La Jolla, CA, USA). 
 
RESULTS 
Expression of “gain-of-function” α4 nicotinic receptor subunits in VTA 
GABAergic neurons. To understand how increased functional expression of α4* 
nAChRs in VTA GABAergic neurons affect behavior, we developed a viral-
mediated gene delivery system to express α4* nicotinic receptor subunits with a 
“gain-of-function” mutation in select neuronal populations allowing for selective 
activation of neurons expressing this subunit with low doses of nicotine that 
minimally activate non-α4* nAChRs.  We engineered an AAV plasmid construct 
containing cDNA encoding the α4 nAChR subunit with a single point mutation, a 
leucine mutated to serine, at the 9´ residue of the pore-forming, M2 domain 
(Leu9´Ser, Figure II-1 A), which renders nAChRs that incorporate this subunit 
significantly more sensitive to nicotine (Labarca et al., 2001).  To visualize 
subunit expression, a YFP tag was included in the M3-M4 intracellular loop 
where it does not interfere with receptor assembly or function (Leu9´Ser α4-YFP) 
(Nashmi et al., 2003, Nashmi et al., 2007).  The cDNA encoding Leu9´Ser α4-
YFP was positioned within the AAV expression vector in the antisense orientation 
and flanked by two pairs of distinct Lox sites (Figure II-1 A).  These Lox sites 
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regulate Leu9´Ser α4-YFP expression by directing recombination of the cDNA 
cassette to the sense orientation in the presence of Cre recombinase (Figure II-1 
A) (Tsai et al., 2009). 
 
The expression vector was packaged into AAV2, a serotype that will infect 
a brain region locally, and viral particles were injected into the VTA of glutamate 
decarboxylase 2 (Gad2)-Cre mice (Gad2VTA: Leu9´Ser) for expression of 
Leu9´Ser α4-YFP subunits selectively in GABAergic neurons.  To verify subunit 
expression in GABAegic neurons, Gad2VTA: Leu9´Ser midbrain slices were 
immunolabeled with either an anti-TH or Gad1/2 antibody.  VTA of infected mice 
exhibited robust expression of Leu9´Ser α4-YFP subunits as indicated by strong 
YFP fluorescent signal selectively in non-DAergic neurons (Figure II-1 B).  To 
determine functional expression of Leu9´Ser α4-YFP subunits in GABAergic VTA 
neurons, patch-clamp recordings were made in Gad2VTA: Leu9´Ser and control 
midbrain slices.  Control Gad2-Cre animals were infected with AAV2 particles 
containing channelrhodopsin within the same vector so that GABAergic neurons 
from control mice will express a non-nAChR membrane protein insensitive to 
nicotinic agonists.  The electrophysiological characteristics of infected neurons, 
as identified by YFP fluorescent signal, were analyzed to confirm incorporation of 
the Leu9´Ser α4-YFP subunit into a nAChR.  Leu9´Ser α4-YFP-infected neurons 
exhibited fast-spiking spontaneous action potentials and lacked an Ih current, 
both characteristics of VTA GABAergic neurons (Figure II-1 C) (Johnson and 
North, 1992).  Single-cell RT-PCR from the cytoplasm of recorded neurons 
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confirmed Gad1 and Gad2 expression in YFP-positive neurons (Figure II-1 D).  
To test for functional expression of the Leu9´Ser α4-YFP subunit, whole cell 
current responses to bath application of 1 mM ACh were recorded in infected 
Gad2-Cre midbrain slices.  ACh elicited robust inward currents in Leu9´Ser α4-
YFP subunit-expressing VTA GABAergic neurons that were significantly larger 
compared to responses from neurons recorded from control slices (Figure II-1 E).  
Together, these data suggest that Gad2VTA: Leu9´Ser mice express the 
Leu9´Ser α4-YFP subunit in GABAergic neurons and the subunit co-assembles 
with endogenous subunits to form “gain-of-function” nAChRs. 
 
Selective activation of VTA GABAergic neurons in Gad2VTA: Leu9´Ser 
mice.  To test the hypothesis that a low dose of nicotine selectively increased 
activation of VTA neurons in nicotine-naïve Gad2VTA: Leu9´Ser mice compared 
to control animals, we challenged each group with saline or an acute dose of 
0.09 mg/kg nicotine and immunolabeled VTA slices for c-Fos expression, an 
immediate early gene that is a marker for neuron activation (Cole et al., 1989).  
Two-way ANOVA indicated a significant main effect of virus expression (F(1,22) = 
29.96, p < 0.001) and nicotine treatment (F(1,22) =31.62, p < 0.001), and a 
significant virus expression x nicotine treatment interaction (F(1,22) =22.23, p < 
0.001) (Figure II-2 A).  Post-hoc analysis indicated that there was a statistically 
significant increase of c-Fos immunopositive VTA neurons from Gad2VTA: 
Leu9´Ser mice receiving 0.09 mg/kg nicotine compared to Gad2VTA: Leu9´Ser 
mice receiving saline injection (p < 0.0001).  In addition, the number of c-Fos 
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immunopositive VTA neurons in Gad2VTA: Leu9´Ser mice was also significantly 
greater than the number of c-Fos immunopositive VTA neurons in nicotine-
treated control animals.  In control mice, 0.09 mg/kg nicotine did not significantly 
increase the number of c-Fos immunopositive VTA neurons compared to saline.  
To determine if nicotine-activated neurons were predominantly non-DAergic, we 
challenged control and Gad2VTA: Leu9´Ser mice with 0.09 mg/kg nicotine and 
double immunolabeled for c-Fos and TH (Figure II-2 B, C).  Two-way ANOVA 
revealed a significant main effect of virus expression (F(1,22) =5.3, p < 0.05) and 
neuron sub-population (F(1,22) =10.0, p < 0.01), and a virus expression x nicotine 
treatment interaction (F(1,22) =4.73, p < 0.05).  Post-hoc analysis indicated that the 
number of TH immunonegative, c-Fos immunopositive neurons in Gad2VTA: 
Leu9´Ser was significantly larger than TH immunopositive, c-Fos immunopositive 
neurons after nicotine challenge (p < 0.01).  The number of TH immunonegative, 
c-Fos immunopositive neurons in Gad2VTA: Leu9´Ser was also larger than the 
number of TH immunonegative, c-Fos immunopositive neurons in control mice 
after nicotine challenge (p < 0.05).  The number of TH immunopositive, c-Fos 
immunopositive neurons in Gad2VTA: Leu9´Ser mice after nicotine challenge 
was small and not significantly different from control mice.  In addition, YFP 
signal could be detected in c-Fos immunopositive neurons in Gad2VTA: 
Leu9´Ser mice but not in control mice (Figure II-2 B). Together, these data 
indicate that 0.09 mg/kg nicotine selectively activates non-DAergic (i.e., 
GABAergic) neurons in Gad2VTA: Leu9´Ser mice. 
 
 57 
Nicotine activation of α4* nicotinic receptors in VTA GABAergic neurons:  
Locomotor effects.  To test the hypothesis that functional upregulation of 
nAChRs in GABAergic neurons may be involved in nicotine tolerance (Nashmi et 
al., 2007), we measured nicotine-induced locomotor activity in response to single 
daily injections of the drug for seven days in Gad2VTA: Leu9´Ser and control 
animals.  Mice were challenged with 0.09 mg/kg nicotine delivered s.c., a dose 
that activated GABAergic neurons in Gad2VTA: Leu9´Ser but had little effect on 
neuronal activation in control mice.  In control mice, 0.09 mg/kg nicotine did not 
significantly modulate locomotor activity compared to saline injection (Figure II-3 
A).  In Gad2VTA: Leu9´Ser mice, one-way ANOVA revealed a significant main 
effect of nicotine injections on locomotor activity (F(3,18) = 7.86, p < 0.01).  Post-
hoc analysis revealed that nicotine significantly depressed locomotor activity 
upon first injection compared to saline (p < 0.01) and tolerance to this 
hypolocomotor response occurred with subsequent injections.  Thus, acute 
activation of nAChRs in VTA GABAergic neurons induces hypolocomotor activity 
which triggers tolerance after subsequent nicotine exposures.  
 
Sensitivity to nicotine reward is modulated by activation of VTA GABAergic 
α4* nicotinic receptors.  To test the hypothesis that functional upregulation of 
VTA GABAergic neurons modulates nicotine reward, the ability of nicotine to 
condition a place preference in Gad2VTA: Leu9´Ser and control mice was 
measured using the CPP procedure.  During training, mice were challenged with 
saline, 0.09 mg/kg or 0.5 mg/kg nicotine (Figure II-3 C, D, Table II-1) delivered 
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s.c.  In control animals, nicotine did not condition a significant place preference in 
response to either dose (Figure II-3 C) similar to previous reports delivering s.c. 
nicotine injections with the CPP procedure in C57BL/6J mice (Hilario et al., 
2012), the background strain of the Gad2-Cre mice.  However, a significant CPP 
in response to 0.5 mg/kg was observed in this strain during withdrawal from 6 
weeks chronic nicotine treatment (Figure II-3 C, inset, significant main effect of 
drug-paired chamber, F(1,20) = 5.97, p < 0.05 and a significant drug-paired 
chamber × chronic treatment interaction, F(1,20) = 10.10, p < 0.01, two-way 
ANOVA on difference scores:  Significant increase in difference score in the 
nicotine-paired chamber between nicotine-dependent and nicotine-naïve mice, p 
< 0.01.  Also see Table 1).  In Gad2VTA: Leu9´Ser mice, two-way ANOVA of 
difference scores (Figure II-3 D) indicated a significant main effect of drug (F(1,26) 
= 18.64, p < 0.001) but not training chamber (F(2,46) = 0.6807, p > 0.05), and a 
significant drug x training chamber interaction (F(2,46)=7.086, p < 0.01).  Post-hoc 
analysis revealed a significant difference between difference scores in the 
nicotine-paired chamber at the dose of 0.09 mg/kg, but not 0.5 mg/kg, nicotine in 
Gad2VTA: Leu9´Ser mice compared to saline (Figure II-3 D).  Repeated 
measures two-way ANOVA of time spent in the drug and saline-paired chamber 
pre- and post-training with 0.09 mg/kg nicotine (Table 1) did not indicate 
significant main effects of training or time spent in either chamber, but did reveal 
a significant training x chamber interaction (F(1,8) = 25.48, p < 0.001).  Post-hoc 
test indicated a significant increase in time spent in the nicotine-paired chamber 
post-training compared to pre-training.  Finally, two-way ANOVA of time spent in 
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the drug-paired chamber pre- and post-training in Gad2VTA: Leu9´Ser mice that 
received 0.09 mg/kg nicotine during training compared to mice that received 
saline in the drug-paired chamber (Table II-1) indicated a significant main effect 
of drug (F(1,15) = 10.32, p < 0.01) and time spent in the drug-paired chamber 
(F(1,15) = 7.97, p < 0.05), and a significant interaction (F(1,15) = 13.19, p < 0.01).  
Post-hoc analysis indicated a significant increase in time-spent in the drug-paired 
chamber post-training with 0.09 mg/kg nicotine compared to saline.  Interestingly, 
after chronic nicotine exposure, Gad2VTA: Leu9´Ser mice did develop a modest 
CPP to 0.5 mg/kg nicotine (repeated measures Two-way ANOVA:  Significant 
training x chamber interaction, F(1,9) = 27.61, p < 0.001.  Significant increase in 
time spent in the nicotine-paired chamber after training, p < 0.05, Table 1).   
While a low dose of nicotine may elicit a CPP in Gad2VTA: Leu9´Ser mice 
by activating GABAergic neurons, it is also possible that nicotine may be 
desensitizing Leu9´Ser α4-YFP nAChRs in VTA GABAergic interneurons, 
reducing endogenous ACh activation of the mutant nAChRs (i.e., blocking 
GABAergic interneuron activity), and thereby disinhibiting DAergic neurons to 
promote reward (Mansvelder et al., 2002).  We hypothesized that if this were 
occurring, then a nAChR antagonist would elicit a similar effect by blocking 
endogenous activity through the Leu9´Ser α4-YFP nAChRs.  Thus, we measured 
the ability of the noncompetitive nAChR antagonist, mecamylamine, to condition 
a place preference in Gad2VTA: Leu9´Ser and control, nicotine-naïve animals.  
In both groups, 1.0 mg/kg mecamylamine failed to significantly condition a place 
preference (Figure II-4 A).  In an additional group of Gad2VTA: Leu9´Ser and 
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control nicotine-naïve animals, we tested whether DHβE, a selective α4β2 
competitive antagonist would be sufficient to disinhibit DAergic neurons and 
condition a place preference.  Training with 0.5 or 2.0 mg/kg DHβE, s.c. in control 
and Gad2VTA: Leu9´Ser mice failed to condition a place preference (Figure II-4 
B).  These data indicate that selective activation of α4* nAChRs in GABAergic 
neurons is sufficient for nicotine reward. 
Gad2VTA: Leu9´Ser mice α4* nAChRs are expressed in VTA GABAergic 
neurons that project to the Lateral Habenula (LHb).  To gain insight into the 
neuronal sub-population(s) of VTA GABAergic neurons that may express the 
Leu9´Ser α4-YFP subunit and elicit nicotine-induced reward in Gad2VTA: 
Leu9´Ser animals, we immunolabeled C57BL/6J midbrain slices with potential 
GABAergic neuronal markers calretinin, calbindin, somatostatin and parvalbumin 
(Figure II-5 A).  Interestingly, we did not detect somatostatin nor parvalbumin 
expression in the area of the VTA that was targeted with our virus expression 
system (that is, the posterior VTA), although somatostatin expression was 
observed in the rostral interpeduncular nucleus as previously described (Zhao-
Shea et al., 2013).  Both calretinin and calbindin immunopositive cells were 
detected (Figure II-5 A).  However, analysis of YFP signal in Gad2VTA : Leu9´Ser 
mice revealed that calretinin and calbindin immunopositive neurons did not 
express YFP, consistent with previous reports that the majority of calretinin- and 
calbindin-expressing VTA neurons are actually DAergic (Olson and Nestler, 
2007).  We next analyzed YFP signal in known VTA efferent brain regions of 
Gad2VTA: Leu9´Ser mice including the NAc, PFC, and LHb, for YFP 
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fluorescence (Figure II-5 B, C).  Interestingly, YFP signal was not detected in the 
PFC or NAc.  However, fluorescence was observed in the LHb.   
 
DISCUSSION 
We expressed Leu9´Ser α4-YFP nAChR subunits in VTA GABAergic 
neurons in an effort to understand how functional upregulation of α4* nAChRs in 
this neuronal subpopulation may contribute to behaviors associated with nicotine 
dependence.  Chronic nicotine upregulates α4* nAChRs selectively in 
GABAergic neurons of the VTA and this is accompanied by an increase in 
functional expression as measured by an increase in nicotine activation of these 
neurons (Nashmi et al., 2007).  It is important to note that if chronic nicotine 
merely upregulated the α4 nAChR subunit and not the β2 subunit then this would 
result in a change in α4β2 nAChR stoichiometry to the low sensitivity (α4)3(β2)2 
subtype (Eaton et al., 2014).  However, a functional increase in activation is 
observed in chronic nicotine-treated animals, suggesting that upregulation of 
both α4 and β2 subunits occurs (Srinivasan et al., 2011), leading to the observed 
increase in nAChR function in GABAergic VTA neurons.  To mimic this 
phenomenon, we chose to express “gain-of-function” α4 nAChR subunits in 
GABAergic VTA neurons instead of wild-type (WT) subunits which would have 
likely changed the α4β2 nAChR stoichiometry to the low sensitivity (α4)3(β2)2 
subtype resulting in a loss of function phenotype. 
In Gad2VTA: Leu9´Ser mice, a low dose of 0.09 mg/kg nicotine was 
sufficient to activate GABAergic neurons.  This same dose failed to significantly 
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activate neurons in control animals.  Interestingly, there were few DAergic 
neurons activated in both control and Gad2VTA: Leu9´Ser mice after low-dose 
nicotine challenge.  Importantly, nicotine was delivered s.c. in these experiments; 
whereas this same dose has been shown to elicit reward in mice when delivered 
i.p, highlighting that routes of nicotine administration yield differences in 
bioavailablility of the drug (Brunzell et al., 2009; Alcantara et al., 2014).   
 
Acute nicotine activation of VTA GABAergic neurons induces 
hypolocomotion.  We assessed how functional upregulation of VTA GABAergic 
neurons may contribute to nicotine tolerance and reward.  Acute nicotine induces 
hypolocomotion in rodents, which is alleviated with multiple nicotine exposures, 
providing a behavioral measure of tolerance (Tapper et al., 2007).  Typically, 
locomotor suppression has been observed in C57BL/6J mice given a dose of 
~0.5 mg/kg nicotine in a novel environment or open field (Salas et al., 2004).  A 
single injection of 0.09 mg/kg nicotine in a novel cage was sufficient to decrease 
locomotor activity in Gad2 VTA: Leu9´Ser but had little effect on locomotor activity 
in control mice.  Interestingly, Gad2 VTA: Leu9´Ser mice developed tolerance to 
this effect with daily low dose nicotine injections, indicating that acute activation 
of VTA GABAergic neurons induces hypolocomotion with subsequent exposures 
eliciting tolerance to this effect.  The mechanism underlying nicotine-induced 
hypolocomotor activity is unknown.  Our data indicate that activation of VTA 
GABAergic neurons may cause the initial nicotine-induced decrease in locomotor 
activity perhaps by inhibiting DA release into the striatum.  However, additional 
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experiments will be needed to determine if the tolerance to this hypolocomotion 
involves α4* nAChRs in GABAergic neurons or, alternatively, triggers a non-
nAChR mechanism that opposes hypolocomotion. 
 
Selective activation of VTA GABAergic neurons by nicotine is sufficient for 
reward.  Previous studies using optogenetic stimulation have shown that 
activation of VTA GABAergic neurons can lead to disruption of reward and 
induce aversion (Tan et al., 2012; van Zessen et al., 2012).  Surprisingly, 
selective activation of VTA GABAergic neurons in Gad2VTA: Leu9´Ser mice using 
a low dose of nicotine conditioned a robust place preference in these animals, 
suggesting that nicotine activation of these neurons may be sufficient for reward.  
Conversely, a more typical “rewarding” dose of 0.5 mg/kg s.c. nicotine (Hilario et 
al., 2012; Smith et al., 2012), failed to elicit a place preference in Gad2VTA: 
Leu9´Ser mice, consistent with a shift in the inverted ‘U’ dose response curve 
often seen with nicotine reward and reinforcement (Picciotto, 2003).  In control 
mice, nicotine failed to condition a place preference at any of the doses tested.  
While stress could be a contributing factor to lack of CPP in control animals, this 
is rendered unlikely as mice were habituated to handling prior to the beginning of 
the CPP assay.  Our results are similar to those of Hilario et al. who 
demonstrated that withdrawal from chronic nicotine exposure was necessary for 
the expression of nicotine reward and that this is correlated with nAChR 
upregulation (Hilario et al., 2012).  Verifying these data, we confirmed that control 
mice withdrawn from chronic nicotine also exhibit a place preference with 0.5 
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mg/kg nicotine compared to nicotine-naïve mice.  Based on data indicating that 
1) increased sensitivity to nicotine reward occurs after chronic nicotine exposure 
and withdrawal, 2) sensitivity to nicotine reward correlates with nAChR 
upregulation (Hilario et al., 2012), 3) upregulation of α4* nAChRs occurs 
selectively in VTA GABAergic neurons (Nashmi et al., 2007) and 4) selective 
activation of functionally upregulated α4* nAChRs in VTA GABAergic neurons 
elicits reward, we suggest that upregulation of α4* nAChRs specifically in VTA 
GABAergic neurons increases sensitivity to nicotine reward. 
How might activation of GABAergic neurons by nicotine elicit reward?  
One possibility is that nicotine desensitizes GABAergic nAChRs reducing 
GABAergic neuron activity and disinhibiting DAergic neurons (Mansvelder et al., 
2002).  Our data indicate that, at least using our expression system, this 
possibility is unlikely because 1) we did not observe increased activation of 
DAergic neurons (as measured by c-Fos induction) after low dose nicotine 
challenge in Gad2VTA: Leu9´Ser neurons and 2) mecamylamine and DHβE failed 
to elicit reward in Gad2 VTA: Leu9´Ser mice.  One caveat to these results is that 
disinhibition of DAergic neurons by nAChR desensitization in GABAergic neurons 
would require that Leu9´Ser α4-YFP nAChRs are predominantly expressed in 
GABAergic interneurons.  In analyzing VTA neuron sub-populations in the 
injection area of Gad2VTA: Leu9'Ser mice, which was focused on the posterior 
VTA, we failed to detect parvalbumin or somatostatin immunopositive neurons; 
whereas calbindin and calretinin neurons were detected, but did not co-localize 
with Leu9´Ser α4-YFP expression, consistent with previous studies indicating 
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that these two populations of neurons are largely DAergic in the VTA (Gerfen et 
al., 1987, Olson and Nestler, 2007).  A more recent study indicates that activation 
of GABAergic neurons via β2* nAChRs is required for DAergic neuron burst 
activity and nicotine self-administration (Tolu et al., 2012).  Thus, nicotine 
activation of GABAergic neurons in Gad2VTA: Leu9´Ser mice could lead to 
increased DAergic neuron bursting and reward.  However, as indicated above, 
increased activation of DAergic neurons, at least with acute nicotine injections, 
was not observed in these animals.  A third and more likely possibility is that a 
portion of VTA GABAergic neurons expressing Leu9´Ser α4-YFP nAChRs 
project to brain regions that, when inhibited, promote reward behavior.  Indeed, 
upon analysis of known VTA projection regions, we found Leu9´Ser α4-YFP 
expression in the LHb.  While GABAergic neurons make up ~35% of VTA 
neurons and little is known about their function within the VTA (Nair-Roberts et 
al., 2008), recent studies indicate that a portion of VTA GABAergic neurons 
innervate the LHb and, when activated, elicit reward (Stamatakis et al., 2013; 
Lammel et al., 2015).  This is accomplished by inhibiting LHb glutamatergic 
inputs to the rostromedial tegmental nucleus (RMTg), which, in turn, disinhibits 
VTA DAergic neurons to promote reward (Hong et al., 2011; Lecca et al., 2011).  
Thus, one mechanism by which nicotine activation of VTA GABAergic neurons 
could elicit nicotine reward is through inhibiting these LHb inputs to the RMTg.  
Future studies should focus on how VTA GABAergic neuron activation alters the 
excitability of these downstream brain regions in the context of nicotine-induced 
reward.  Our data suggest that activation of functionally upregulated α4* nAChRs 
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in VTA GABAergic neurons confers increased sensitivity to nicotine reward.  
These data indicate that nAChR subtypes specifically expressed in VTA 
GABAergic neurons may be good molecular targets for therapeutics to aid in 
smoking cessation. 
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Figure II-1.  Viral-mediated gene delivery of “gain-of-function” α4 nAChR 
subunits in VTA GABAergic neurons.  A) Depiction of the Leu9´Ser α4-YFP 
subunit cDNA viral plasmid.  Cre-recombinase flips the Leu9´Ser α4-YFP subunit 
cDNA in the sense orientation.  The viral particles containing this plasmid were 
intracranially injected into the VTA of Gad2-Cre mice for selective expression in 
VTA GABAergic neurons.  B) Top, expression of Leu9´Ser α4-YFP subunits in 
non-TH neurons of Gad2-Cre mice.  Brain slices from infected mice were 
immunolabeled for TH to identify DAergic neurons (red, top, left).  YFP 
fluorescence was detected indicating Leu9´Ser α4-YFP subunit expression 
(green, top, middle).  Merged signals revealed little co-localization of Leu9´Ser 
α4-YFP subunit expression with DAergic neurons (top, right).  Photomicrographs 
(bottom panels) of a representative VTA midbrain section from Gad2-Cre mice 
expressing Leu9´Ser α4-YFP subunits showing neurons immunolabeled for Gad 
(left) that also express Leu9´Ser α4-YFP subunits (middle).  The merged 
photomicrograph (right) shows co-localization of GAD and YFP signals.  C) Cell-
attached (top) and whole-cell voltage-clamp (bottom) recordings from a putative 
VTA GABAergic neuron from a Gad2-Cre mouse midbrain slice.  GABAergic 
neurons typically have a high frequency of firing (8-20 hz, top) and lack of a 
hyperpolarizing activated current, Ih (bottom).  D) At the end of each recording, 
single neuron RT-PCR was performed to verify GAD expression in a GABAergic 
neuron (left lanes) or TH expression in a DAergic neuron (right lanes).  E) Whole-
cell voltage-clamp recordings from a control VTA GABAergic neuron in Gad2-Cre 
midbrain slice (top, left) and an Leu9´Ser α4-YFP-expressing GABAergic neuron 
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in a Gad2-Cre midbrain slice (top, right).  ACh was bath applied for 3 min as 
indicated by the bar above each trace.  Average inward current from control 
infected (n = 5) and Leu9´Ser α4-YFP (n = 8) infected VTA GABAergic neurons.  
**p < 0.01, two-tailed t-test. 
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Figure II-2.  Selective activation of VTA GABAergic neurons by nicotine in 
Gad2VTA: Leu9´Ser mice.  A) Summed average number of c-Fos immunopositive 
(c-Fos(+)) neurons in VTA of Control (n = 6/group) and Gad2VTA: Leu9´Ser mice 
(n = 7/group) after challenge with saline or 0.09 mg/kg nicotine.  ***p < 0.001 
number of c-Fos(+) neurons in Gad2VTA: Leu9´Ser mice after nicotine challenge 
compared to saline challenge.  ^^^ p < 0.001 number of c-Fos(+) neurons in 
Gad2VTA: Leu9´Ser mice after nicotine challenge compared to the number of c-
Fos(+) neurons in Control mice after nicotine challenge.  B) Representative 
photomicrographs illustrating c-Fos expression (red) in VTA sections taken from 
Control (top panels) or Gad2VTA: Leu9´Ser mice (bottom panels) mice after 0.09 
mg/kg nicotine challenge.  Neurons exhibiting TH immunoreactivity are labeled in 
blue (left panels); whereas YFP expression is labeled in yellow (right panels).  C)  
Summed average number of TH(+), c-Fos(+) and TH(-), c-Fos(+) neurons in the 
VTA of Control (n = 6) and Gad2VTA: Leu9´Ser mice (n = 7) after challenge with 
0.09 mg/kg nicotine.  ** p < 0.01 number of TH(+), c-Fos(+) neurons compared to 
the number of TH(-), c-Fos(+) neurons in Gad2VTA: Leu9´Ser mice after nicotine 
challenge.  ^ number of neurons that are TH(-), c-Fos(+) in Gad2VTA: Leu9´Ser 
mice after nicotine challenge compared to the number of neurons that are TH(-), 
c-Fos(+) in Control mice after nicotine challenge. 
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Figure II-3.  Selective activation of VTA GABAergic neurons by nicotine is 
sufficient for nicotine-induced hypolocomotion and reward.  A)  Summed 15 min 
total locomotor activity after saline injection, or daily injection of 0.09 mg/kg 
nicotine in Control mice (n = 7).  B) Summed 15 min total locomotor activity after 
saline injection, or daily injection of 0.09 mg/kg nicotine in Gad2VTA: Leu9´Ser 
mice (n = 7).  ** p < 0.01 compared to saline challenge.  Difference scores 
indicate the time spent in the nicotine- or saline-paired chamber after training 
minus the time spent in the nicotine- or saline-paired chamber prior to training in 
C) Control or D) Gad2VTA: Leu9´Ser mice in response to 0 (saline) (n = 10/group), 
0.09 (n = 9/group), and 0.5 mg/kg nicotine (n = 8/group).  C) Inset: Difference 
scores in the CPP assay in response to 0.5 mg/kg nicotine from WT mice 
previously exposed to six weeks of nicotine (n = 8) or vehicle (n = 8).  *** p < 
0.001 nicotine-paired chamber compared to saline-paired chamber, ^ p < 0.05 
nicotine-paired chamber in dependent mice compared to nicotine-paired 
chamber in nicotine-naïve mice.  ^^ p < 0.01 nicotine-paired chamber compared 
to saline in the drug-paired chamber.  Two-way ANOVA, Bonferroni Post-hoc 
test. 
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Figure II-4.  nAChR antagonists do not condition a place preference in Gad2VTA: 
Leu9´Ser mice.  A)  Difference scores in the CPP assay in response to 1.0 mg/kg 
mecamylamine in Control and Gad2VTA: Leu9´Ser mice (n = 10/group).  B) 
Difference scores in the CPP assay in response to 0.5 or 2.0 mg/kg DHβE in 
Control mice (n = 7) and Gad2VTA: Leu9´Ser mice (n = 8 and 6, respectively).  
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Table II-1.  Total time spent (in seconds) in nicotine (Nic)- and saline (Sal)-paired 
chambers of the CPP assay pre-training (Pre) and post-training (Post). 
 
* p < 0.05, **p < 0.01. Post-training compared to Pre-training, Two-way ANOVA 
with repeated measures (training and nicotine/saline treatment), Bonferroni post-
hoc test.  ^^^ p < 0.001 time spent in the nicotine-paired chamber post-training 
compared to time spent in the control nicotine-paired chamber (i.e., group that 
received saline in the “drug-paired” chamber).  Two-way ANOVA with repeated 
measures (Pre/Post time spent in the Nic-paired chamber).  Bonferroni post-hoc.  
## p < 0.01, time spent in the nicotine-paired chamber post-training in nicotine-
dependent animals compared to time spent in the nicotine-paired chamber in 
nicotine-naïve animals.  Two-way ANOVA with repeated measures (Pre/Post 
time spent in the Nic-paired chamber).  Bonferroni post-hoc. 
 
 
 
 
 
 
 
 
Virus (Nic, mg/kg) Sal (Pre, s) Sal (Post, s) Nic (Pre, s) Nic (Post, s) 
Control (Sal) 379.7±20.86 315.7±48.44 280.2±18.88 335.5±45.96 
Control (0.09) 339±9.444 309.3±47.33 271.1±14.35 249.5±45.42 
Control (0.5) 334.9±32.69 341.1±21.41 284.9±17.82 299.3±24.08 
Leu9´Ser  (Sal) 365.6±25.91 315.6±53.89 261.7±21.01 239.0-±34.97 
Leu9´Ser (0.09) 347.6±21.93 205.9±27.43 257.1±17.7 437.9±37.28**,^^^ 
Leu9´Ser (0.5) 303.3±24.92 240.4±18.14 293±13.92 319.2±37.3 
Leu9´Ser (0.5, Chronic 
Nicotine) 382±10.11 294.1±19.78 306.8±16.57 376.1±19.33*,^^^ 
Virus (Mec, mg/kg) Sal (Pre, s) Sal (Post, s) Mec (Pre, s) Mec (Post, s) 
Control (1.0) 409.2±28.42 352.5±40.04 282.3±29.93 317.6±43.69 
Leu9´Ser (1.0) 386.1±25.30 300.1±36.56 288.2±23.48 354.0±35.28 
Virus (DHβE, mg/kg) Sal (Pre, s) Sal (Post, s) DHβE (Pre, s) DHβE (Post, s) 
Control (0.5) 363.8 ± 31.05 342.9 ± 24.21 311.7 ± 30.39 315.1 ± 22.15 
Control (2.0) 447.6±31.12 332.2±38.96 226.3±32.76 285.9±44.42 
Leu9´Ser (0.5) 396.1±23.09 287.7±41.97 244±22.59 348.2±41.85 
Leu9´Ser (2.0) 383.1±16.36 352±55.83 309.4±12.95 309.6±55.02 
Treatment/Drug Sal (Pre, s) Sal (Post, s) Nic (Pre, s) Nic (Post, s) 
Vehicle/Nicotine 367±20.3 328.5±23.48 268.8±18.67 263.7±26.09 
Chronic Nicotine 
/Nicotine 400.2±29.79 263.2±23.39 261.1±15.01 379.6±26.02*,## 
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Figure II-5.  GABAergic neurons mediating reward in Gad2VTA: Leu9´Ser mice 
include projection neurons to the lateral habenula.  A) Representative 
photomicrographs illustrating calretinin (top, left panel), calbindin (bottom, left 
panel), parvalbumin (top, right panel), and somatostatin (bottom, right panel) 
immunolabeling (red) in C57BL/6J midbrain sections.  Insets depict distinct 
localization of calretinin or calbindin (red) compared to YFP expression (yellow) 
in Gad2VTA: Leu9´Ser mice.  B) Depiction of a coronal section from a Gad2VTA: 
Leu9´Ser mouse used for analysis of GABAergic projections.  The 
photomicrograph illustrates YFP signal in the VTA.  C) Representative 
photomicrographs from cortical (top), striatal (middle) and epithalamic (bottom) 
sections from the Gad2VTA: Leu9´Ser mouse in panel B.  ventral tegmental area:  
VTA; interpeduncular nucleus:  IPN; mammillary nucleus:  ml; prefrontal cortex:  
PFC; nucleus accumbens:  NAc; anterior commissure: aca; lateral habenula:  
LHb; medial habenula:  MHb.       
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CHAPTER III. 
EXPRESSION OF “GAIN-OF-FUNCTION” α4* NICOTINIC ACETYLCHOLINE 
RECEPTORS IN VTA GABAERGIC NEURONS DOES NOT INDUCE ANXIETY 
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ABSTRACT 
Nicotine withdrawal syndrome is a major contributing factor to smoking relapse.  
How chronic nicotine consumption changes the neural pathways involved in 
nicotine withdrawal symptoms such as anxiety remains unknown. Furthermore, 
chronic nicotine exposure results in the upregulation of high-affinity nicotinic 
acetylcholine receptors (nAChRs) in the GABAergic neurons of the VTA (Nashmi 
et al., 2007; Xiao et al., 2009; Renda et al., 2014) neurons implicated in eliciting 
negative affective behavior (Tan et al., 2012; van Zessen et al., 2012). Yet it is 
unknown whether nAChR upregulation promotes anxiety in the absence of 
nicotine. To test the hypothesis that overexpression of high-affinity, α4* nAChRs 
in VTA GABAergic neurons induces anxiety-like behavior, “gain-of-function” α4* 
nAChRs (Leu9´Ser α4-YFP) were expressed in VTA GABAergic neurons of 
nicotine naïve, adult Gad2-Cre male mice (Gad2VTA: Leu9´Ser).  A battery of 
anxiety-related behavioral tests was performed on Gad2VTA: Leu9´Ser and 
control mice to assess for anxiety-related behavioral differences. The Gad2VTA: 
Leu9´Ser mice demonstrated no significant changes in behavior from control in 
the Open Field, Elevated Plus Maze or Marble Burying Test.  Together, these 
results suggest that upregulation of α4* nAChRs in VTA GABAergic neurons 
does not contribute to anxiogenic behaviors that accompany nicotine withdrawal. 
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INTRODUCTION 
Despite reports that tobacco smoking reducing life expectancy by 10 years, 
about one in five Americans are active smokers (Jha et al., 2013).  One of the 
barriers to successful smoking cessation is the emergence of negative affective 
withdrawal symptoms such as increased anxiety. The intensity of an affective 
withdrawal symptom experienced during abstinence predicts the likelihood to 
relapse (Piasecki et al., 2000).   Furthermore, stressful imagery increased 
negative affect and nicotine craving in withdrawn smokers (McKee et al., 2011), 
suggesting that chronic nicotine exposure alters an individual’s reaction to stress.  
How sustained nicotine consumption alters the brain to exaggerate anxiety 
symptoms during nicotine withdrawal is not well understood.   
Nicotine binds onto the nicotinic acetylcholine receptors to modulate neuronal 
firing activity and ultimately alter behavior (Picciotto et al., 2008).  These 
pentameric ligand-gated cation channels are expressed throughout the brain and 
modulate a multitude of processes, ranging from attention to learning (Cordero-
Erausquin et al., 2000; D’Souza and Markou, 2011).  Nicotine exhibits an 
inverted U-shaped response that is attributed to various factors such as dose 
administered, specific nAChR subtypes and receptor activation state (Picciotto, 
2008; Di Biasi and Dani, 2011). Nicotine induced anxiety-like behaviors in 
rodents at sub-rewarding doses (Irvine et al., 2001a; Biala and Budzynska, 
2006), while rodents withdrawn from chronic nicotine exhibited anxiogenic 
behavior (Damaj et al., 2003; Salas et al., 2004, 2009; Zhao-Shea et al., 2014).  
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However, it is not know if changes in nAChRs that occurs with chronic nicotine 
use are involved in nicotine withdrawal syndrome. 
Chronic nicotine use induces upregulation of nAChRs in select areas of the brain 
including the Ventral Tegmental Area, although the contribution of these 
upregulated nicotinic receptors in nicotine withdrawal is unknown. Within the 
VTA, nicotinic receptors are upregulated in both DAergic and GABAergic 
neurons (Nashmi et al., 2007; Baker et al., 2012; Renda et al., 2014; Henderson 
et al., 2015).  One of the predominant upregulated nAChR subunit combination, 
or subtype, is the α4β2* subtype, which has been shown to play a substantial 
role in mediating reward in the mesocorticolimbic DAergic pathway (Tapper et al., 
2004; Maskos et al., 2005; Pons et al., 2008; McGranahan et al., 2011).  
Previous research suggests that α4β2* nAChRs are involved in anxiety-like 
behaviors (Ross et al., 2000; Yohn et al., 2014), but what brain regions are 
involved are unclear. 
The ventral tegmental area, a region often associated with reward signaling and 
substance abuse, has also been implicated in aversion and anxiety behavior.  
Although DAergic neurons exhibit increased activity in response to rewarding 
stimuli, DAergic neurons are also activated with aversive stimuli (Joshua et al., 
2008) and project to regions involved in aversion, such as the LHb (Lammel et 
al., 2014).  Optogenetic stimulation of VTA DAergic projections in the PFC 
identified a subset of DAergic neurons induced anxiety-like behavior (Gunaydin 
et al., 2014)  Furthermore, expression of corticotropin releasing factor (CRF), a 
neuropeptide involved in modulating stress, is increased in VTA DAergic neurons 
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during chronic nicotine exposure (Grieder et al., 2014).  CRF expression in the 
VTA is necessary to incite anxiety-like behaviors during nicotine withdrawal 
through CRF type 1 receptors in the ventral IPN (Zhao-Shea et al., 2015).  These 
data suggest that the VTA can contribute to the emergence of nicotine 
withdrawal symptoms.   
The GABAergic subpopulation of the VTA is also implicated in negative affective 
behavior.  Optogenetic activation of VTA GABAergic neurons disrupts sucrose 
consumption and conditions place aversion (Tan et al., 2012; van Zessen et al., 
2012).  Furthermore, inhibition of VTA GABAergic neurons disinhibits DAergic 
neurons (Bocklisch et al., 2013).  VTA GABAergic neurons could contribute to 
withdrawal symptoms by inhibiting DAergic firing and resulting in an anhedonic 
state (Tye et al., 2012).  While anhedonia does not directly cause anxiety it could 
coincide with anxiety-inducing behaviors and exacerbate the anxious state (Gold, 
2015).     
In the previous chapter, mice overexpressing “gain-of-function” Leu9´Ser α4* 
nAChRs in GABAergic neurons of the VTA (Gad2VTA: Leu9´Ser) exhibited 
increased conditioned place preference when given nicotine.  It is possible the 
expression of Leu9´Ser α4* nAChRs on VTA GABAergic neurons induced mice 
into a hyperanxious state.  Increased anxiety-like behavior was observed in 
knock-in mice expressing the Leu9´Ser α4 nAChR subunit (Labarca et al., 2001). 
The experiments in Chapter II may have inadvertently identified a VTA 
subpopulation contributing to anxiogenic behaviors. Administering a low dose of 
nicotine could possibly ameliorate the anxious state. 
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To assess if Leu9´Ser α4* nAChR expression in the VTA GABAergic neurons 
contributes to anxiety-like behaviors, Leu9´Ser α4* nAChRs were selectively 
overexpressed in GABAergic neurons of the VTA of Gad2-Cre male mice.  These 
“gain-of-function” α4* nAChRs are meant to mimic upregulation α4* nAChRs in 
VTA GABAergic neurons that occurs with chronic nicotine use.  Mice were 
assessed for anxiety-like behavior in the open-field test (OFT), the elevated plus 
maze (EPM) and the marble burying test (MBT).  These tests were chosen 
because they measure spontaneous responses to a slightly aversive 
environment. Mice expressing Leu9´Ser α4-YFP* nAChRs in GABAergic neurons 
of the VTA exhibited a slight trend to be anxiolytic in all three tasks compared to 
control, without impacting locomotor activity.  This suggests that α4 nAChR 
upregulation in VTA GABAergic neurons has no anxiogenic effects.   
 
MATERIALS AND METHODS 
Mice. Genetically engineered male mice containing Cre recombinase coding 
sequence inserted in the 3’-UTR of the Gad2 gene (B6N.Cg-Gad2tm2(cre)/Zjh/J) 
from Jackson Labs (≥ 8 weeks) were used in this study.  All mice were group 
housed, with up to 5 mice per cage, to mitigate anxiety caused by single housing.  
All animal handling and care was done in accordance to the University of 
Massachusetts Medical School IACUC. 
 
Stereotaxic Injections Adeno Associated Virus serotype 2 viral particles 
packaged either with pAAV-zsGreen (control) or pAAV-Ef1a-DIO-L9´S-α4-EYFP 
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(Leu9´Ser) were obtained through the UMass Medical School Viral Vector Core.  
Construct engineering has been previously described (Chapter 2).  Concentration 
of virus ranged from 1.0 to 2.5 X 10^12 vp/ml.  Viral particles were stereotaxically 
injected into the VTA of Gad2-Cre mice according to coordinates provided by 
Franklin and Paxinos (-3.3 (AV); +/-0.3 (ML), -4.0 (DV)).   After recovering from 
anesthesia, mice received an injection of 200 µl 5% glucose and 10 mg/kg 
ketoprofen to aid in recovery and reduce pain, respectively.  Mice were kept 
under observation for 4 weeks after infection before used in any behavioral assay 
to allow for optimal gene expression.   
 
Immunofluorescence. After the completion of an anxiety test, animals were 
anesthetized with 200 mg/kg sodium pentobarbital (intraperitoneal injection) and 
transcardiacally infused with 10 ml of chilled 0.1 M PBS following with chilled 4% 
(w/v) paraformaldehyde dissolved in 0.1 M PBS.  The brains were harvested and 
placed in cold 4% paraformaldehyde for 2 h before submerging in 30% sucrose.  
Brains were then sectioned into 30-micron slices using a microtome (Leica, 
Buffalo Grove, IL, USA).  An AxioCam MRm camera (Carl Zeiss Microscopy 
GmbH, Jena, Germany) attached to a Zeiss Axiovert inverted fluorescent 
microscope equipped with Zeiss filter sets 38HE, 49, and 20 was used to acquire 
fluorescent images.  Zeiss objectives EC-Plan-NEOFLUAR 20x were used to 
view and capture images.  Images were processed using Axiovision v.4.8.2. The 
VTA was located using morphology of nearby brain regions.  Mice that did not 
express YFP fluorescence were excluded from analysis.   
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Open Field. Experiments were performed in the morning, around 10:00-11:00 
am.  One hour prior to testing, mice were placed into the experimental room to 
habituate to their surroundings.  Mice were placed in the center of a 40 cm by 36 
cm opaque plexiglass arena to assess overall locomotor activity and behavioral 
responses to open spaces.  Before the test, light intensity was measured in the 
center and the periphery to assure that light intensity was the brightest in the 
center of the arena.  The mouse was placed in the center of the field and allowed 
to freely explore for 15 minutes.  The center of the open field was defined as a 20 
cm by 18 cm field in the center of the arena through the Ethovision tracking 
software (Noldus, Wageningen, Netherlands), while the perimeter was defined as 
the remaining area around that field.  Total distance moved, velocity and time 
spent in either the center or the perimeter was recorded through the Ethovision 
software.   After each test, the arena was wiped down with 70% ethanol. 
 
Elevated Plus Maze. To reduce anxiety from being placed in a novel 
environment, mice were placed in the experimental room one hour prior to 
experiment.  A plus-shaped plexiglass platform, elevated 45 cm from the ground 
(Med Associates, St. Albans, VT) was used for this experiment.  Two arms were 
enclosed with opaque plexiglass walls (30 x 5 x 15 cm), while the other two arms 
were left exposed (30 x 5 x 0.25 cm).  Infrared photobeams were installed at 
each arm entrance to track entries and amount of time spend in each arm.  A 
60W fluorescent lamp was placed 100 cm directly over the center of the maze to 
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discourage time spent in the center.  Mice were placed in the center of the maze 
and allowed to explore the apparatus for five minutes. Number of entries and 
total time spent in each arm was recorded using the MED-PC IV software (MED 
Associates, Inc.).  The arms of the EPM were wiped clean in between trials.    
 
Marble Burying Test. Two days prior to testing, mice were habituated each day 
for 45 min to a testing cage containing a 5-6 cm layer of bedding.  Fifteen clean 
1.5 cm glass marbles were placed on the testing cage floor in a 5 x 3 matrix, 4 
cm apart from each other the day of testing.  A mouse was placed into a cage 
and left to explore for 30 minutes.  Mice were carefully removed from the test 
cage to not disturb test cage bedding after 30 minutes and returned to their home 
cage.  Number of marbles buried was assessed, with a marble that was covered 
at least 2/3 of its depth by bedding being considered buried.   
 
Statistical Analysis. All data sets were tested for normality before statistical 
analysis. All behavioral experiments were analyzed using two-tailed t-tests.  Data 
was analyzed using GraphPad Prism (GraphPad Software, La Jolla, CA, USA).  
 
RESULTS 
To mimic upregulation triggered by chronic nicotine specifically in VTA 
GABAergic neurons, male Gad2-Cre mice were stereotaxically injected with 
viruses packaged with either control or Leu9´Ser constructs.  After 4 weeks, both 
groups of mice were tested in the OFT, the EPM and the MBT.  The OFT is a 
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locomotor activity-based assay that assesses anxiety-like behavior based on the 
amount of time a mouse spends in the open center versus the perimeter.  There 
was no significant difference in time spent in the center (p = 0.7121, non-
significant, n.s.) (Figure III-1 A) or time spent in the perimeter (p = 0.6819, n.s.) 
(Figure III-1 B) between Gad2VTA: Leu9´Ser and control mice.  There were no 
significant differences in locomotor activity between Gad2VTA: Leu9´Ser and 
control as determined by total distance traveled (p = 0.8588, n.s.) (Figure III-1 C) 
and mean velocity (p = 0.0651, n.s.) (Figure III-1 D).  These data indicate that 
increasing α4 nAChR expression does not alter novelty based locomotor activity. 
The EPM is considered the standard test in measuring anxiety-like behaviors and 
the properties of potential anxiety therapeutics.  It involves placing a mouse on a 
raised platform with two extending arms of the platform enclosed and two arms 
left exposed.  A separate cohort of control and Gad2VTA: Leu9´Ser was tested on 
the EPM for height-induced anxiety.  Although there was a trend towards 
Gad2VTA: Leu9´Ser mice spending more time in the open arms, there is no 
significant difference in time spent in the open arms (p = 0.2168, n.s.) (Figure III-
2 A).  There is no significant difference in time spent in the closed arms between 
Gad2VTA: Leu9´Ser mice and control mice (p = 0.1014, n.s.) (Figure III-2 B).  
There is no significant difference in time spent in the junction between Gad2VTA: 
Leu9´Ser mice and control mice (p = 0.3147, n.s.) (Figure III-2 C).  To account for 
locomotor activity, total number of entries into each arm was tabulated. There 
were no significant differences between Gad2VTA: Leu9´Ser and control mice in 
number of arm entries (p = 0.0629, n.s.) (Figure III-2 D). 
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To further compliment the previous anxiety tests, the Marble Burying Test was 
performed with a separate group of mice.  This test is unique from the previous 
two tests it utilizes the natural tendency for mice to bury objects when stressed.   
Anxiety levels are assessed by the number of marbles submerged in bedding.  
There was a non-significant reduction of marbles buried in the Gad2VTA: 
Leu9´Ser mice compared to control mice (p = 0.1108, n.s.) (Figure III-2 E).     
After the completion of an experiment, mice brains were assessed for Leu9´Ser 
α4-YFP or control expression in the VTA through fluorescent microscopy (Figure 
III-3).  Mice that did not exhibit fluorescence in the VTA were excluded from the 
study. 
 
DISCUSSION 
The goal of this study was to investigate how overexpression of “gain-of-function” 
α4* nAChRs in VTA GABAergic neurons contributes to anxiety during nicotine 
withdrawal.  Increased anxiety is a common affective symptom experienced by 
smokers during a period of nicotine withdrawal (Hughes, 2007).  Upregulation of 
nAChRs occurs with chronic nicotine use (Staley et al., 2006; Nashmi et al., 
2007; Muhkin et al., 2008; Henderson et al., 2015), yet it is unknown if 
upregulation contributes to nicotine withdrawal symptoms.  Activation of VTA 
GABAergic neurons via optogenetic techniques induces aversion and disrupts 
appetitive behaviors (Tan et al., 2012, van Zessen et al., 2012), while selectively 
activating VTA GABAergic neurons with sub-rewarding doses of nicotine 
 86 
increases reward sensitivity (Ngolab et al., 2015).  Furthermore, mice expressing 
Leu9´Ser α4 nAChRs exhibited anxiety-like behaviors (Labarca et al., 2001).   
To test whether overexpresion of α4 nAChRs specifically in VTA GABAergic 
neurons increases anxiety-like behavior, adult Gad2-Cre male mice transduced 
with a “gain-of-function” α4 nAChR subunit (Gad2VTA: Leu9´Ser) or control virus 
in VTA GABAergic neurons were subjected to a series of anxiety-like behavioral 
tests.  These tests were chosen because they measure non-conditioned, natural 
anxiety-like responses (Belzung and Griebel, 2001).  Smokers can experience 
heightened anxiety from nicotine withdrawal without a conditioned response.  
The anxiety-like tests used in these experiments set two natural tendencies of 
mice in conflict with one another to measure anxiety-like responses.  Mice 
naturally avoid bright open spaces but also explore novel places.  The general 
consensus is that a mouse spending relatively more time in open, bright spaces 
is considered to be less anxious. There were no significant differences in anxiety-
like behaviors in any of the three tests.  Together, these data suggest that 
Leu9´Ser α4* nAChRs in VTA GABAergic neurons have no significant effect on 
inducing anxiety.  These observations are in agreement with current literature, 
because α4KO mice exhibit heightened anxiety in the EPM (Ross et al., 2000),  
suggesting an anxiolytic role for α4* nAChRs.  Indeed, anxiety responses were 
decreased in chronically nicotine treated mice when given an α4* nAChR partial 
agonist (Yohn et al., 2014).  Although not significantly different, Gad2VTA: 
Leu9´Ser mice exhibit anxiolytic tendencies during testing (Fig III-2A, 2E).   
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All three anxiety-like tests use the motility of a mouse, either to move to a certain 
area or displace bedding, as a proxy for anxiety.  A major variable that can 
confound results is the overall locomotor activity of a mouse.  In the OFT and 
EPM, no difference in locomotor activity was detected, therefore indicating 
neither the injection nor overexpression of Leu9´Ser α4* nAChRs damaged the 
locomotor circuitry.  Acute administration of nicotine has been shown to elicit 
hypolocomotor effects, specifically through activation of α4* nAChRs on VTA 
GABergic neurons (Tapper et al., 2007; Ngolab et al., 2015).  The major 
contributors of ACh to the VTA are from the laterodorsal tegmentum (LDTg) with 
65% of these projections synapsing on to non-DAergic VTA neurons (Garzón et 
al., 1999).  Stimulating LDTg projections to the VTA resulted in increased 
conditioned place preference (Lammel et al., 2012).  Although “novel” 
environments may cause activation of VTA DAergic neurons (Schultz, 2010), 
perhaps the exposure to open fields does not provide a strong stimulus to induce 
acetylcholine release from LDTg neurons and induce hypolocomotion.   
One major caveat of these studies is the low number of mice in several of the 
experiments.  Low sample size reduces the statistical power and therefore 
decreases the possibility of detecting a true effect (Button et al., 2013).  Although 
none of the results were statistically significant in this chapter, the low power due 
to sample size increases the probability of false negatives confounding the 
interpretation of these results.  Increasing the sample size to a set number 
determined by power analysis would allow for a statistically robust assessment of 
the data. 
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It is possible that Leu9´Ser α4* nAChRs expressed in Gad2VTA: Leu9´Ser mice 
are not functional.  Leu9´Ser α4* nAChRs delivered through this system have 
been previously characterized to be functional with low doses of nicotine 
(Chapter II).  All mice that were used in this study were verified for Leu9´Ser α4 
expression via YFP immunofluorescence.  To further improve on this 
assessment, quantifying the number of YFP(+) GABAergic neurons infected 
within the VTA would further determine the contribution of the Leu9´Ser nAChR 
subunit to the behavioral changes.  
Recent studies have shown that other pathways are active in the expression of 
nicotine withdrawal symptoms.  The habenulo-peduncular pathway has been 
highly implicated in the somatic and affective withdrawal symptoms (Salas et al., 
2004, 2009; Zhao-Shea et al., 2013, 2015).  Furthermore, a recent study 
indicates that CRF from the VTA can influence the activity of the IPN, a critical 
nucleus for the expression of nicotine withdrawal symptoms (Zhao-Shea et al., 
2015). It has been hypothesized that nicotine dependence is the result of 
neurological adaptations that occur to facilitate drug consumption (Koob and 
Moal, 2005; D’Souza and Markou, 2011).  There are other neuroadaptations that 
occur with chronic nicotine, such as increased CRF production in DAergic 
neurons (Grieder et al., 2014).  It is possible that increasing activation of α4* 
nAChRs on VTA GABAergic neurons through upregulation could increase 
inhibition of DAergic neurons.  Inhibition of DAergic neurons by VTA GABAergic 
neurons could possibly trigger CRF production and release.  Additionally, these 
data suggest possible segregation of nAChR subunits involved in nicotine reward 
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and withdrawal, or at least neuronal subpopulations within specific regions that 
could be involved in withdrawal.  VTA GABAergic neurons may not specifically 
contribute to withdrawal through α4* nAChRs, and it could be that upregulation of 
these α4* nAChRs could be a compensatory mechanism in response to the 
overactivation of pathways involved with withdrawal, such as the habenula-
peduncular pathway.  Understanding the dynamics behind nicotinic receptor 
upregulation may help with developing efficacious therapies.    
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Figure III-1.  Expression of the Leu9´Ser α4 nAChR subunit does not hinder 
locomotor activity.  A) Total amount of seconds control (n = 5) or Gad2VTA: 
Leu9´Ser (n = 5) mice spend in the center of the open field arena. B) Time spent 
in the periphery C) Total distance mice moved throughout the test, in 
centimeters. D) Mean velocity of mice, calculated as centimeters per second.  
Error bars are s.e.m. 
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Figure III-2. Gad2VTA: Leu9´Ser mice do not exhibit any overt changes in 
anxiety-like behavior compared to control mice.  A) Total time in seconds 
Gad2VTA: Leu9´Ser (n = 11) and control mice (n = 16) spent in the Open Arms of 
the Elevated Plus Maze.  B) Total time in seconds spent in the Closed Arms of 
the Elevated Plus Maze.  C) Total time spent in the junction.  D) Total entries into 
either closed or open arms.  E) Number of marbles buried by control (n = 6) and 
Gad2VTA: Leu9´Ser (n = 8) mice.  Error bars are s.e.m. 
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Figure III-3.  Verifying viral-mediated gene expression in mouse brains.  
Depiction of a coronal section from mice used in anxiety tests.  Representative 
pictographs illustrate YFP signal from (top) Gad2VTA:  Leu9´Ser and (bottom) 
control mice.   
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CHAPTER IV. 
DISCUSSION 
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Chronic nicotine exposure incites a multitude of compensatory modifications 
within the brain to facilitate persistent nicotine use.  One of these 
neuroadaptations is the upregulation of nAChRs, the ligand-gated cation channel 
that nicotine binds onto to incite nicotine tolerance.  Behavioral studies using 
nicotine-withdrawn mice observed changes in consumption behavior, reward 
sensitivity and anxiety (Irvine et al., 2001; Hilario et al., 2012; Renda et al., 2014).  
Of importance, chronic nicotine leads to the upregulation of α4 nAChR subunits, 
a subunit critical in nicotine-reward behaviors, (Flores et al., 1992; Tapper et al., 
2004; Pons et al., 2008; McGranahan et al., 2011) particularly in midbrain 
GABAergic neurons (Nashmi et al., 2007; Xiao et al., 2009; Renda and Nashmi, 
2014).  However, it is not clear whether upregulated α4* nAChR are acted upon, 
for increased receptor binding could reflect the binding of nAChR in a high affinity 
yet desensitized conformation (Quick and Lester, 2002; Picciotto et al., 2008).  
Several studies suggest that chronic nicotine treatment brings forth increased 
nAChR activation, (Wonnacott, 1990; Vallejo et al., 2005; Srinivasan et al., 2011)  
yet the role of activation of α4* nAChR on VTA GABAergic neurons in nicotine 
dependence behaviors is unclear.   
To gain insight into how VTA GABAergic-specific upregulation of α4* nAChR 
contributes to behaviors involved in nicotine dependence we developed a Cre-
regulated, viral-mediated technique to selectively express an α4-YFP nAChR 
subunit containing a 9´ leucine to serine point mutation in the TM2 domain (Leu 
9´ Ser) (Labarca et al., 1995; 2001).   Mice with mutations at the 9´ position of 
TM2 in an nAChR alpha subunit are hypersensitive to agonist, and have been 
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used to understand the contributions of a nAChR subunit to neuronal activity and 
overall behavior (Labarca et al., 2001; Fonck et al., 2003, 2005; Orb et al., 2004; 
Tapper et al., 2004, 2007; Drenan et al., 2008; Drenan and Lester, 2012).  The 
VTA contains a heterogenous population of neurons that when activated can 
elicit either rewarding or aversive behavior (Tsai et al., 2009; Lammel et al., 
2012, 2015; Gunyadin et al., 2014).  Nicotine exhibits an ‘inverted U’ dose 
response, in that different concentrations trigger opposite behaviors (Picciotto, 
2008), providing a challenge in developing effective therapies for smoking 
cessation.  Therefore, understanding how nicotine affects the GABAergic subset 
of VTA neurons would help further discern the contributions of this subpopulation 
to nicotine dependence.   
We hypothesized that direct activation of VTA GABAergic neurons through 
upregulated α4* nAChRs would elicit aversion, based on previous studies that 
activated VTA GABAergic neurons through optogenetic stimulation (van Zessen 
et al., 2012, Tan et al., 2012). Sub-threshold doses of nicotine sufficient to 
activate VTA GABAergic neurons that expressed functional Leu9´Ser α4* 
nAChRs induced nicotine hypolocomotor activity and increased nicotine reward 
sensitivity (Chapter II).  Previous studies observed in mice withdrawn from 
chronic nicotine exhibited increased nicotine place preference and consumed 
more nicotine-laced water which coincided with increases in nAChR binding and 
α4* nAChR expression (Hilario et al., 2012; Renda and Nashmi, 2014).  Our data 
imply direct activation of upregulated α4* nAChR VTA GABAergic neurons 
increased the rewarding properties of nicotine during a period of withdrawal.  
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Furthermore, the overexpression of α4* nAChRs had no effect on anxiety-like 
behaviors often associated with nicotine withdrawal.  
The technique described within this thesis provides a novel method into studying 
the contributions of α4* nAChRs in a cell-specific manner.  This is the first time to 
my knowledge that overexpressing a nAChR subunit in adult mice expressing 
endogenous α4 nAChR subunits has been done.  One advantage of this 
technique over transgenic and knockout mice is the ability to bypass 
developmental issues brought forth by the manipulation of the α4 nAChR subunit 
(Muller et al., 1999; Picciotto and Wickman, 1998; Champtiaux and Changeux, 
2004). Although the technique holds tremendous potential, several technical 
issues must be addressed to appropriately interpret these results.  These issues 
include finding a reliable marker to identify VTA GABAergic neurons, quantifying 
GABAergic neurons expressing α4* Leu 9´ Ser nAChRs as well as ensuring that 
the α4* Leu 9´ Ser nAChRs are expressed within the pVTA. 
VTA GABAergic neurons make up 20-35% of the total VTA population (Margolis 
et al., 2006; Yamaguchi et al., 2007; Nair-Roberts et al., 2008; Chieng et al., 
2011).  The Gad2-Cre mouse driver line, previously used to target GABAergic 
neurons (Tan et al., 2012; Taniguchi et al., 2011), was used in these studies to 
ensure the greatest amount of VTA GABAergic neurons were infected.  Glutamic 
acid decarboxylase (Gad) is the enzyme involved in the production of GABA and 
comes in two isoforms, Gad1 and Gad2 (Gad 67 and Gad 65, respectively) 
(Soghomonian and Martin, 1998).  Cre expression was restricted to the majority 
of GABAergic cells in the Gad2-Cre driver line and colocalized with 90% of 
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Gad1+ cells (Taniguchi et al., 2011).  Indeed, the Gad2-Cre mouse driver line 
restricted Leu9´Ser α4* nAChRs expression to non-DA, GAD1/2 neurons 
(Chapter II).   
It has recently come to light that mouse Cre-driver lines may not confer cell-
specificity within the VTA (Lammel et al., 2015; Stuber et al., 2015) due to the 
heterogeneous nature of the VTA.  For example, there are small populations of 
TH+VGluT2+ that make up a small fraction of the VTA (Yamaguchi et al., 2015), 
although studies using a VGluT2-Cre driver line suggest the percentage of VTA 
glutamatergic neurons is higher than expected (Hnasko et al., 2010; Tecuapetla 
et al., 2010).  VTA TH+Gad1/2+ neurons also have been identified that send 
inhibitory projections to the LHb (Stamatakis et al., 2013), but later defined as 
GABAergic (Stuber et al., 2015).  The TH+Gad1/2+ positive neurons found within 
the VTA released GABA but not DA (Stamatakis et al., 2013); therefore, if 
TH+GAD+ neurons expressed Leu9´Ser α4-YFP* nAChRs in the Gad2-Cre driver 
mice, GABA but not DA would likely be released.  Although these observations 
occurred in a different mouse driver line, this does not necessarily confirm that 
the Gad2-Cre driver line expresses nAChRs exclusively in GABAergic neurons.  
Notably, astrocytes can express Cre in the Gad2-Cre driver line (Taniguchi et al., 
2011).  Although not widely studied, nicotine can induce increases in intracellular 
Ca++ through activating α4* nAChRs on astrocytes (Oikawa et al., 2005).  Not 
much is known about how non-neuronal cells contribute to VTA function and 
nicotine reward, and further studies would reveal another layer of complexity 
within the VTA circuitry.  
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The number of cells infected may not properly reflect the number of cells that 
actually express GABA.  Cre-driver mouse lines were used to identify 
subpopulations of neurons that express a certain gene (Taniguichi et al., 2011).  
However, the presence of transcript does not necessarily indicate protein 
expression as observed in TH-Cre mice (Stamatakis et al., 2013; Yamaguchi et 
al., 2015).  Further tests to measure protein production or transmitter release 
should follow these studies to ensure the appropriate subpopulation is assessed.  
Cre-driver lines may provide an overestimate of the percent of neurons releasing 
a particular neurotransmitter, for low levels of Cre recombinase may be 
necessary to initiate homologous recombination and the expression of Cre-
restricted genes.  Although the cell population may not produce enough GABA 
for vesicular release, the production of Cre recombinase would distinguish it as a 
GABA producing cell.  This would increase the number of false positives and not 
appropriately identify the subpopulation’s function.  The Gad2-Cre driver line was 
generated through inserting the Cre coding cassette into the Gad2 gene, so it is 
unlikely that Gad2 expression differ from Cre expression (Taniguichi et al., 2011).   
Like all genetically engineered mice, Cre-driver mouse lines are susceptible to 
developmental issues that affect adult behavior.  Transgenic ChAT-Cre mice 
demonstrated severe cognitive deficits compared to their control line due to 
overexpression of vescicular acetylcholine transporter (Kolisnyk et al., 2013)..  
One of the objectives of performing the experiments in Chapter III was to identify 
differences in baseline behaviors that could ripple into other behavioral assays.  
In my hands, I did not observe any overt differences in anxiety-like behavior 
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(Chapter III).  However, these observations may be premature and more tests 
need to be performed to confidently conclude that the Gad2-Cre driver line has 
no deficits in the behaviors performed in this thesis.   
Production of the Leu9´Ser α4 nAChR subunit is driven by the constitutive 
promoter EF1a. This strategy allows for the robust expression of the Leu9´Ser α4 
nAChR in order to drive the incorporation of the subunit into a nAChR.  
Overexpressing the nAChR subunit may override protein degradation 
mechanisms that would prevent the Leu9´Ser α4 nAChR from being expressed.  
However, the continuous expression of Leu9´Ser α4 nAChR subunits may not 
reflect endogenous nAChR overexpression instigated by nicotine or allow for 
transcriptional regulation.  Furthermore, overexpression may initiate unforeseen 
issues, such as non-physiological nAChR combinations (subtypes), cell death 
and ectopic expression of nAChRs in a neuron.   
Expression of “gain-of-function” nAChRs can be lethal in mice homozygous for 
the mutant nAChR (Labarca et al., 2001; Orr-Urtreger et al., 2000).  Studies done 
in mice expressing the Leu9´Ser α4 nAChR suggest that the number of Leu9´Ser 
α4 nAChR subunits within a nAChR decreases overall viability (Labarca et al., 
2001; Fonck et al., 2003).  However, it is hypothesized the overall percentage of 
nAChRs containing 2 or more Leu9´Ser α4 nAChR subunits is ~4% (Fonck et al., 
2003).  This implies that there are additional regulatory mechanisms regulating 
nAChR subunit integration into a nAChR.  The baseline electrophysiological 
characteristics recorded from Gad2VTA: Leu9´Ser brain slices exhibit similar 
properties found in VTA GABAergic neurons, suggesting Leu9´Ser α4 nAChR 
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subunit expression does not perturb overall function (Chapter II).   Preliminary 
studies using a construct containing a Cre-restricted, unmutated α4-YFP nAChR 
subunit in TH-Cre driver mouse line suggests that overexpression of this subunit 
does not affect cell viability.  Follow-up studies quantifying overall number of VTA 
GABAergic neurons in Gad2-Cre Leu9´Ser  and Gad2-Cre α4 mice would further 
distinguish whether the behavioral changes are due to viable GABAergic neurons 
expressing the Leu9´Ser -YFP subunit and not to the lack of GABAergic cells.  
TUNEL staining or other cell death assay would further determine the overall 
cytotoxic properties of the Leu9´Ser -YFP nAChR subunit. 
Overexpression could lead to the formation and expression of non-physiological 
α4* nAChR subtypes.  Xenopus oocytes expressing nAChRs Leu9´Ser  α4 
nAChRs subunits and wildtype β2 subunits were sensitive to choline, a byproduct 
of nicotine metabolism that activates α7 nAChRs, at physiological concentrations 
(Alkondon et al., 1997; Labarca et al., 2001).  This could affect studies that 
require subsequent nicotine administration, such as nicotine tolerance and 
nicotine CPP.  The same study measured the effects of choline in neuronal 
progenitor cells from mice heterozygous for the Leu9´Ser α4 nAChR subunit and 
observed smaller currents activated by choline than seen in cells from wildtype 
mice (Labarca et al., 2001).  Furthermore, the presence of WT α4 nAChRs may 
prevent choline-mediated activation in my system, as it is unknown whether 
choline sensitivity is dependent on the number of Leu9´Ser α4 nAChR subunits 
in a nAChR.  Studies in Xenopus oocytes reported that Leu9´Ser α4* nAChRs 
exhibited a decrease in the rate of desensitization (Revah et al., 1995; Labarca et 
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al., 1995).  This may ultimately affect the baseline activity of nicotine-mediated 
GABAergic activation that may not reflect the characteristics of nAChRs in the 
(α4)2(β2)3 conformation.  More thorough analysis in measuring the rate of 
desensitization of VTA GABAergic neurons expressing Leu9´Ser -YFP nAChRs 
through biophysical techniques would address these issues. 
Neuronal nAChRs can be found both on the soma as well as presynaptic 
dendrites and terminal boutons (Laviolette and van der Kooy, 2004; Gotti and 
Clementi, 2004; Changeux, 2010).  Chronic nicotine induces an increase of α4-
YFP* nAChRs particularly in the dendrites over the soma of primary neuronal cell 
cultures (Nashmi et al., 2004) suggesting that upregulation preferentially occurs 
in certain areas of the neuron.  Overexpression of the Leu9´Ser α4 nAChR 
subunit can promote the expression of non-physiological Leu9´Ser α4* nAChRs 
expressed throughout the neuron.  Activation of Leu9´Ser α4* nAChRs in 
GABAergic terminals located in the NAc could lead to the inactivation of inhibitory 
inputs and incite DA transmitter release which may explain reward signaling 
despite low number of TH+/c-Fos+ cells within the VTA (Chapter 2), which may 
or may not be caused by upregulation of nAChRs.  Although the goal of these 
studies was to uncover possible roles of α4* nAChR-mediated activation in VTA 
GABAergic neurons, overexpression may mask the subtle contributions nAChRs 
have on overall neuronal membrane potential.  
Overall increase of available α4 nAChR subunits could shift the overall dose 
response independent of the “gain-of-function” mutation.  The amount of α4β2* 
nAChRs expressed is dependent on the internal pool of β2 nAChR subunits 
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contained in the endoplasmic recticulum that is regulated by proteasome 
degradation. Indeed, upregulation of α4β2* expression is dependent on the 
reduction of β2 nAChR degradation (Darrow et al., 2005; Rezvani et al., 2009; 
Govind et al., 2012).  Furthermore, it is thought that nicotine acts as a chaperone 
to initiate the formation of high-sensitivity nAChRs, so despite increasing the 
potential pool these nAChRs are regulated by the presence of nicotine 
(Srinivasan et al., 2010). It is possible that overexpression of α4-YFP subunits 
could lead to the formation (α4)3(β2)2 nAChRs.  Nicotinic receptors in this 
stoichiometry are considered low sensitivity (Nelson et al., 2003).  Therefore, 
overexpression would result in the expression of low-sensitivity nAChRs, which is 
contrary to what was observed with c-Fos immunoreactivity and whole-cell patch 
clamp recordings (Chapter II). Furthermore, Xenopus oocyte studies indicate that 
at least one Leu9´Ser nAChR variant is sufficient for increasing sensitivity to 
agonist (Labarca et al., 1995).  Therefore, the possibility that increasing nAChR 
expression leads to the abundance of low sensitivity (α4)3(β2)2 is bypassed by 
using the Leu9´Ser nAChR variant.  In fact, more Leu9´Ser α4* nAChRs further 
helps to selectively activate VTA GABAergic neurons.  Regardless, expressing a 
non-mutated, Cre restricted α4 nAChR subunit would address potential shifts in 
the dose response based on increased receptor number or altered subunit 
composition and serve as a physiological control rather than ChR2-YFP. 
Radioligand binding studies could also assess whether an increase of α4 nAChR 
expression in VTA GABAergic neurons leads to an increase of the number of α4* 
nAChRs. To further mitigate concerns due to overexpression, using a moderate 
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expressing promoter to drive Leu9´Ser -YFP expression (to reflect endogenous 
expression levels and upregulation of α4* nAChRs) would be preferable to the 
strong promoter used here. Refinement of this approach, by using a construct 
producing more modest levels of expression, using a Cre-dependent WT (L9´L) 
α4 receptor as control, and more riogorous quantitation of the number of cells 
infected in each animal will greatly improve the ability to draw conclusions from 
studies such as those presented here.  
Because this is first time this technique has been implemented, detection of YFP 
fluorescence in VTA GABAergic neurons was deemed sufficient to validate that 
animals had hypersentive receptors and were appropriate to examine for 
changes in behavior.  Injections were aimed towards the pVTA, due to previous 
studies suggesting that various drugs of abuse, including nicotine, act in a sub-
region specific manner to induce reward (Zangen et al., 2002; Rodd et al., 2005; 
Ikemoto et al., 2006; Zhao-Shea et al., 2011). The intent of these studies was to 
investigate how selective activation of α4* nAChRs affects VTA GABAergic 
neurons and downstream behaviors.  Although the AAV2 serotype is thought to 
exhibit minimal spread, animals with YFP expression throughout the whole VTA 
were included in data analysis.  The VTA is a relatively small region and often 
YFP expression was found both in the aVTA as well as the pVTA. Mice that did 
not exhibit detectable YFP fluorescence were classified as “sham” injections and 
excluded from the study.  Mice that were injected in areas outside of the VTA 
such as the substantia nigra were included only if there was YFP expression in 
the VTA; otherwise, the mouse was excluded from further behavioral studies.    
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These criteria, although minimal, serve as a foundation for future studies to 
improve upon this technique.  In future, it should be possible to distinguish the 
contributions of the aVTA from the pVTA. GABAergic neurons within each 
subregion can elicit vastly different responses to drugs such as ethanol (Guan et 
al., 2012).  Therefore, expression of “gain-of-function” nAChRs in both 
GABAergic neuronal subpopulations may obfuscate interpretations.  However, 
these differences in the optogenetic studies and my studies could be explained 
by innervation of these particular subregions.  Quantifying how many YFP 
neurons are expressed in the pVTA versus the aVTA, and correlating these 
numbers with the behavioral responses of individual animals would provide 
insight to this question.   
Additional experiments in quantifying expression would further support the 
efficacy of this technique. Although one study utilizing Cre-driver mice has 
indicated small populations can induce behavioral changes (Brown et al., 2012), 
it would be useful to quantify the number of GABAergic neurons needed to 
increase nicotine reward sensitivity.  Several caveats in the system have 
precluded this assessment, which are discussed below along with suggestions 
on how to address these issues. 
The identification of GABAergic neurons within the VTA is not trivial.  The VTA is 
a heterogenous population that has been undercharacterized until recent tools 
were developed to delve into the neural circuitry (Lammel et al., 2015).  These 
tools highlighted previously neglected differences observed with the criteria 
established for identifying different VTA subpopulations.  Although antibodies are 
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available to detect GABAergic markers, few quantification studies were done 
utilizing immunohistochemistry, and markers used to identifiy cortical GABAergic 
neurons may not overlap with VTA GABAergic neurons (Olsen and Nestler, 
2007).  Mouse studies that quantify VTA GABAergic neurons use markers 
expressed on presynaptic terminals assumed to synapse primarily on GABAergic 
neurons, which may highlight a subset of VTA GABAergic neurons (Van Zessen 
et al., 2012; Tan et al., 2012), or Gad67-GFP mice (Chieng et al., 2012, Taylor et 
al., 2014).  Cre recombinase is driven by the Gad65 promoter and could be used 
as an additional marker for GABAergic neurons.  However, in my hands, I have 
not been able to detect Cre recombinase expression using immunofluorescence.  
Previous studies have verified the expression of Cre recombinase in the Gad65-
Cre mouse driver line, so Cre recombinase is expressed at levels sufficient to 
activate floxed inverted constructs but not high enough to detect through 
immunofluorescence (Taniguichi et al., 2012).  Previous VTA GABAergic 
quantification studies utilized in situ hybridization (Yamaguchi et al., 2007; Nair-
Roberts et al., 2008), which can be coupled with fluorescence detection.  Overall, 
improving techniques in detecting VTA GABAergic neurons would help with 
appropriate quantification of Leu9´Ser  infected neurons.    
Tracking Leu9´Ser α4 nAChR subunit expression via the YFP fused to the 
intracellular loop provides a direct method to track subunit expression and 
improves on previous studies that relied on lentiviruses and radioligand binding 
to verify α4 expression (Maskos et al., 2005; Pons et al., 2008; Exley et al., 
2011).  In my hands, when detected, Leu9´Ser expression was similar to what is 
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observed in mice expressing α4* nAChRs tagged with YFP (α4-YFP) (Nashmi et 
al., 2007; Renda et al., 2014).  However, detecting YFP fluorescence has been 
troublesome at times and others have reported struggling to detect YFP 
fluorescence from α4-YFP mutant subunits despite observing substantial effects 
with nicotine (R. Loring, personal communication).   
One explanation for poor YFP detection is amount of YFP protein expressed is 
insufficient for detection through standard fluorescent microscopy.  The 
expression of one nAChR subunit containing the Leu9´Ser mutation was 
sufficient to drastically increase the EC50 of an overall nAChR compared to non-
mutated nAChRs in Xenopus oocytes (Labarca et al., 1995).  Therefore, strong 
YFP fluorescence may not be detected in cells despite a significant change in 
behavior. Our microscopy equipment is not equipped to detect fluorescence at 
single receptor resolution, and using equipment with higher resolution may help 
with locating YFP expression.  Detection and quantification of α4-YFP was done 
using the α4-YFP expressing mice in conjunction with advance microscopy 
techniques, in that YFP expression was abundant (Nashmi et al., 2007, papers 
discussing the technique).  Furthermore, YFP emission is prone to diffusing in 
the brain, leading to poor fluorescence signal (cite).  Other studies using the α4 
nAChR-YFP mice have resorted to immunostaining for YFP and detecting with 
the Alexa 594 fluorophore (Bailey et al., 2013).  In my studies, immnunostaining 
for YFP using an Alexa 488 fluorophore improved detection (Chapter 2) and 
future studies could follow suit, albeit reducing the convenience the fluorescent 
protein directly attached to the nAChR subunit.  An HA tag was also inserted into 
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the M3-M4 nAChR intracellular loop and serve as an alternative marker of 
exogenous α4 nAChRs either through immunofluorescence or western blot 
(Nashmi et al., 2004). 
In contrast with previous studies, I used adeno associated virus (AAV), a class of 
small icosahedral parvoviruses, to mediate gene delivery. AAV is ideal to use in 
non-dividing cells such as neurons for long-term gene expression (Lentz et al., 
2012; Wu et al., 2010).  Yet, one of the limiting factors of AAV is the size of the 
packaged genome containing the transgene as well as other elements to induce 
and improve gene expression.  AAV packaged with genomes exceeding 5.0 kb 
were sheared at the 5´ end of the genome resulting in the reduction of 
expression efficiency (Wu et al., 2010).  Although I observed an increased 
current in YFP+ neurons with nicotine, the overall size of the expression cassette 
was 5.8 kb (Chapter II).  Therefore, expression of YFP could be reduced, 
attributed to technicalities due to viral packaging.  Several options are available 
to overcome issues due to viral packaging.  Decreasing the genome size by 
reducing the size of the promoter or other regulatory elements without sacrificing 
expression would address this issue (Choi et al., 2014).  Changing the serotype 
of the adenovirus to AAV5, which is reported to have better expression in 
neurons and can package genomes up to 8.9 kb, could considerably improve 
transgene expression (Allocca et al., 2008).  Switching viral vectors to lentivirus 
would allow for genomes up to 8 kb to be packaged into a viral particle (Lentz et 
al., 2012).  Furthermore, altering the design of the construct to take into account 
neurons that are infected but do not express Cre recombinase, as was done in 
 108 
Tolu et al., 2012, would further help assess the percentage of cells infected with 
virus and provide a better measure of infection efficiency.   
In light of this, YFP fluorescence may not fully account for the amount of 
Leu9´Ser α4* nAChRs expressed within the brain.  In fact, measuring Leu9´Ser  
expression through YFP fluorescence may be underestimating overall 
expression.  This has serious implications for results in Chapter II using YFP as 
an indicator of Leu9´Ser-α4*-expressing neurons and as a tracer.  Although YFP 
fluorescence is detected in the LHb in Gad2VTA: Leu9´Ser mice, this should not 
be interpreted as the only projection. It is entirely possible that Leu9´Ser α4*  
nAChRs are expressed on VTA GABAergic projections to the NAc and the PFC, 
but the low amount of Leu9´Ser necessary to activate these regions may be 
below the limit of detection.  A cursory analysis of Gad65 and Gad67-Cre mice 
brains infected with doubly floxed ChR2-YFP in the VTA identified a greater 
amount of YFP fluorescence in the LHb compared to the NAc and the PFC 
(Taylor et al., 2014), suggesting a substantial population of VTA GABAergic 
neurons project to the LHb.  The amount of projections to the LHb may explain 
why Leu9´Ser -YFP projections were detected in the LHb over PFC and NAc 
(Chapter II).   
One may also question whether the Leu9´Ser α4 nAChR subunit is expressed 
solely in VTA GABAergic neurons if YFP detection is unreliable.  Expression of 
the Leu9´Ser α4 nAChR subunit at low levels in DAergic neurons would explain 
why increased reward was observed in Gad2VTA: Leu9´Ser mice.  Preliminary 
studies in HEK293 cells indicate co-transfection of Cre Recombinase is 
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necessary for Leu9´Ser -YFP expression.  If Cre Recombinase was not 
necessary, YFP expression should be detected in cells not transfected with Cre 
Recombinase.  Furthermore, if expression of the Leu9´Ser α4 nAChR subunit in 
DAergic neurons did not result in excitotoxicity, then I hypothesize that 0.09 
mg/kg nicotine would induce more TH+ C-Fos+ neurons in Gad2VTA: Leu9´Ser 
mice based on previous studies utilizing mice expressing hypersensitive α4* 
nAChR subunits (Hendrickson et al., 2010; Zhao-Shea et al., 2012).  Although 
the mutation may be different, the overall result is the expression of “gain-of-
function” α4* nAChRs.  Improving detection of the Leu9´Ser α4 nAChR subunit 
would further address this issue. 
Because of variable expression of the YFP tag and the difficulty to detect 
GABAergic neurons, it has been difficult to quantify VTA GABAergic neurons that 
express the Leu9´Ser  subunit through immunoreactivity in brain tissue.  The 
method developed to quantify α4-YFP expression in VTA GABAergic neurons 
developed by Nashmi and colleagues (2007) would assist in YFP detection.  
Using alternative markers or additional antibodies to boost fluorescence signal 
may also aid in detection.  However, quantification through brain slices can 
increase the number of false positives.  As an alternative, Fluorescence 
Activated Cell Sorting (FACS) could assess the percent of VTA cells expressing 
the Leu9´Ser  subunit through YFP or HA fluorescence. FACS has been 
successfully utilized to analyze neuronal cell populations (Guez-Barber et al., 
2011, 2012; Schwarz, 2015).   This technique sorts a heterogenous population 
into homogenous groups based on size and fluorescent expression. Even using 
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one fluorescent marker such as HA would provide a HA+ and HA- homogenous 
population that can be analyzed by fluorescence intensity further analyzed for 
differences in gene expression.  One major drawback is the large number of cells 
needed to do this analysis and therefore the large number of animals needed to 
generate a sufficient amount of data.  Related to this drawback, it would be 
difficult to analyze small regional subpopulations if the whole VTA is extracted for 
analysis.  However, FACS would provide a better way to identify potential genetic 
markers within a heterogenous population such as the VTA, including potential 
VTA GABAergic markers.  Coupling of laser-capture microscopy for sample 
collection and gene analysis methods refined for assessment of very small 
samples (e.g., single-cell PCR) would also improve the functional 
characterization of VTA subregions. 
Expressing the Leu9´Ser nAChR in Gad2-Cre, α4 null mouse in order to rescue 
α4 nAChR expression may improve YFP detection by allowing the Leu9´Ser -
YFP subunit to be incorporated into the receptor without competion from  
endogenous α4 expression.  This approach also address the potential concerns 
about exogenous nAChRs expressed due to the abundance of α4 nAChRs 
discussed earlier.  This approach improves upon the studies done by Maskos et 
al., 2005 and Pons et al., 2008 by further studying how cell-type selective rescue 
affects behavior.  Indeed, previous studies re-expressing the β2 nAChR subunit 
specifically in DAergic or GABAergic of β2 KO mice have found that expression 
of the subunit is important for shaping burst firing activity in DAergic neurons 
(Tolu et al., 2012). Knocking out α4 nAChR subunits specifically in DAergic 
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neurons decreased nicotine reward but not overall reward, implicating the α4 
nAChR subunit as important in nicotine reward behavior (McGranahan et al., 
2012).  However, similar to what is observed in DAergic neurons of Leu9´Ser 
knock-in mice, exclusively re-expressing the Leu9´Ser nAChR variant may 
reduce the viability of GABAergic neurons.  It is possible that endogenous α4 
expressed in the Gad2-Cre mice could be buffering the cytotoxic effects brought 
forth by the Leu9´Ser  subunit (Fonck et al., 2003).   A separate control group of 
mice expressing the non-mutated α4-YFP nAChR subunit in VTA GABAergic 
neurons would further determine whether the effects observed with nicotine are 
due to re-expressing α4 nAChRs or to the “gain-of-function” variant.  This would 
be an excellent experiment to compliment the observations in the previous 
chapters and provide more evidence on how VTA GABAergic neurons, through 
α4* nAChRs, affect behavior.   
Studies utilizing mice containing a leucine to alanine point mutation in the TM2 
(Leu9´Ala), have been used to further implicate the importance of the α4 nAChR 
subunit in nicotine reward (Tapper et al., 2004, 2007; Zhao-Shea et al., 2008). 
The Leu9´Ala α4 nAChR knock-in mouse line does not exhibit any 
developmental defects, unlike the Leu9´Ser α4 nAChR mouse. Furthermore, 
concentration response studies in Xenopus oocytes expressing muscle nAChR 
subunits indicate the Leu9´Ser nAChR confers higher sensitivity to agonist than 
Leu9´Ala nAChRs (Revah et al, 1995).  It may be beneficial to use this mutation 
in my viral-mediated gene overexpression system, especially in the proposed 
rescue experiments, in order to circumvent the possibility of reduction of cell 
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viability and provide a moderate level of nicotine sensitivity.  Gad2-Cre mice 
infected with a similarly designed Leu9´Ala virus exhibited changes in locomotor 
activity but not in CPP nor anxiety.  I hypothesize endogenous α4 nAChRs are 
masking the Leu9´Ala “gain-of-function” properties.   The Leu9´Ala mutation has 
not been characterized in a subunit receptor manner, and the number of mutated 
subunits is important for the overall sensitivity of a nAChR, then the addition of 
endogenous α4 within a Leu9´Ala α4 nAChR could possibly reduce the overall 
nAChR sensitivity. 
As mentioned in the discussion section in Chapter III, one of the limitations of the 
study was the low sample size in several of the experiments.  The danger of 
interpreting data from low sample groups or small effect sizes is the conflation of 
the actual observed effect.  These inadequately powered studies are susceptible 
to type II errors or false negatives.  Errors of this type fail to reject the null 
hypothesis (the hypothesis that the effect observed is due to chance) so non-
significant results due to this error may be statistically significant with increasing 
sample size.   In other words, type II errors prematurely accept the null 
hypothesis, hence the term ‘false negative’.  Low powered studies are implicated 
with other biases, such as changes in effect magnitude depending on the 
analytical test used (‘vibration of effects’), publication bias and selective data 
analysis (Ioannidis et al., 2008; Button et al., 2013).  Increasing the sample size 
in several of the studies would definitely address this issue, but more 
consideration into experimental design must be done beforehand.   
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Animal studies are limited by time, availability and cost.  Determining a sample 
size beforehand with a priori power analysis would provide a minimum number of 
subjects needed to observe an effect that could possibly reject the null 
hypothesis (Button et al., 2015).  The term “power” refers to probability that the 
null hypothesis is rejected and is an indicator of the ability of a test to properly 
assess for the desired effect.  Variables such as effect size, the probability of 
false positives and negatives occurring also factor into the power analysis.  
Determining effect size depends on prior research.  Studies infecting Leu9´Ser 
α4* nAChRs into VTA GABAergic neurons had not been performed before, but 
the data from the present experiments can be used as the framework for 
establishing sample size for future studies.  However, additional factors, such as 
percentage of GABAergic neurons expressing in Leu9´Ser α4* nAChRs could 
affect the effect size, and proper assessment of this need to be done before 
further experiments are to be done.  Understanding this may help factor into the 
effect size needed for appropriate power analysis.   
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Fig IV-I. Upregulation of α4* nAChRs alters multiple VTA GABAergic 
subpopulations in the mesocorticolimbic dopaminergic pathway to increase 
nicotine reward.  A simplified schematic of the VTA neuronal subpopulations, 
illustrating the projections of the DAergic neurons forming the mesocorticolimbic 
DAergic pathway along with GABAergic projection neurons and interneurons. 
The flower-like symbols indicate α4* nAChRs upregulated with chronic nicotine. 
 
IV.A. The role of functional VTA GABAergic α4* nAChRs in reward 
Nicotine acts upon the brain, particularly through the VTA DAergic neurons, to 
promote continued and compulsive consumption (Benowitz, 1996, 1999; Biasi 
and Dani, 2011).  Although much has been done to assess how nicotine 
activates nAChRs to modulate VTA DAergic activity, not much is known about 
how nicotine acts upon VTA GABAergic neurons.  The observation that selective 
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activation of upregulated α4* nAChRs on VTA GABAergic neurons by nicotine is 
sufficient to increase nicotine reward sensitivity is a curious one because it 
contradicts previous findings done in VTA GABAergic neurons.  The current 
hypothesis of how VTA GABAergic neurons are involved in the VTA reward 
microcircuitry is though inhibition, either by directly hypopolarizing VTA GABAeric 
neurons, indirect silencing from other regions such as the RMTg, or inactivating 
nAChRs on VTA GABAergic by chronic nicotine (Johnson and North, 1992a; 
Mansvelder et al., 2002; Jhou et al., 2009).   My results do not necessarily refute 
the possibility of inhibition of GABAergic neurons contributes to reward signaling, 
as we observed a trend for place preference in Gad2VTA: Leu9´Ser when blocking 
α4* nAChRs with DHβE (Chapter II).  However, there may be other mechanisms 
in which VTA GABAergic neurons augment nicotine reward through upregulated 
α4* nAChRs.  
Many studies have shown that cues associated with nicotine use can facilitate 
relapse.  Cues paired with nicotine intake can reinstate nicotine-seeking 
behaviors (Liu et al., 2006, Patterson and Markou 1999, Donny et al., 1999).  
Previous studies in rodents observe increased VTA GABAergic neuron activity 
during reward anticipation (Steffensen et al., 2001; Cohen et al., 2012).  
Increasing activation of VTA GABAergic neurons through the overexpression of 
Leu9´Ser α4* nAChRs may strengthen anticipation behavior by elevating 
GABAergic neuronal activity with 0.09 mg/kg nicotine during the training session 
of CPP.  This would somewhat explain the increased time spent in the nicotine-
paired chamber with Gad2VTA: Leu9´Ser mice (Chapter II).  High-affinity nAChRs 
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in VTA GABAergic as well as DAergic neurons have been shown to be 
necessary in shaping the firing activity of DAergic neurons with nicotine exposure 
(Tolu et al., 2012).  Increasing nAChR activation on GABAergic neurons may 
further shape the firing activity of the DAergic neurons by increasing the amount 
of spikes within a burst.  This parameter has been implicated in higher DA 
released into the NAc, with more spikes indicating more DA released (Tolu et al., 
2012).  Further studies measuring DA release in the VTA in Gad2VTA: Leu9´Ser 
mice with 0.09 mg/kg nicotine would provide insight into this question.   
However, previous studies have observed abolished sucrose consumption and 
avoidance with optical activation of VTA GABAergic neurons (Van Zessen et al., 
2012; Tan et al., 2012). However, it is unclear whether ChR2-YFP expression 
was restricted to the VTA (Tan et al., 2012).  Although the coordinates indicated 
that the pVTA was targeted, there was no attempt to distinguish between aVTA 
from pVTA.  There is evidence suggesting that posterior VTA GABAergic 
neurons are different from anterior VTA GABAergic neurons (Guan et al., 2012).  
Therefore, the overall activation of both regions may result in one behavior as 
opposed to the activation of a discrete part of the VTA.  Therefore, it is plausible 
that selective activation of GABAergic neurons in the pVTA can elicit one 
behavior while overall activation of the VTA results in another behavior.  These 
behavioral differences could explain the ‘Inverted U’ response observed with 
different doses of nicotine (Picciotto, 2008).   
Further going into the regional differences in the VTA, GABAergic transmission to 
DAergic neurons in one region could have opposing effects on overall behavior.  
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It is thought that DAergic neurons that project to the prefrontal cortex reside in 
the medial VTA while DAergic neurons that project to the NAc reside in the 
lateral VTA (Lammel et al., 2012).  These populations exhibit different 
electrophysiological characteristics (Lammel et al., 2014).  DAergic neurons that 
project to the PFC are thought to be anxiogenic (Gundayin et al., 2014), so 
activation of GABAergic interneurons that inhibit PFC-projecting DAergic neurons 
may decrease activation.  However, whether nAChRs are upregulated on 
GABAergic neurons in a region-specific manner remains to be determined. 
GABAergic neurons in the VTA project to other regions in the brain involved in 
reward (Taylor et al., 2014) (Fig IV-1).  Gad2VTA: Leu9´Ser mice expressed 
Leu9´Ser α4 nAChR projections in the LHb (Chapter II), a brain area associated 
with aversion (Hong et al., 2011; Lammel et al., 2012).  Activating inhibitory 
projections from the VTA to the LHb induced reward through an indirect feedback 
loop that disinhibits DAergic neurons (Stamatakis et al., 2013).  It is possible that 
α4* nAChR upregulation occurs in neurons that project to the LHb to lead to 
increased reward sensitivity.  I detected Leu9´Ser α4-YFP* nAChR fluorescence 
in the LHb of Gad2VTA: Leu9´Ser mice (Chapter II).  Although signaling through 
the proposed meso-habenular GABAergic loop may be insufficient to account for 
the strong increase in nicotine reward sensitivity observed in Gad2VTA: Leu9´Ser 
mice. Signaling for VTA DA disinhibition could be watered down and ultimately 
lost due to the number of brain regions necessary and the multiple inputs each 
region receives from other brain regions.  If anything, upregulation of nAChRs in 
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VTA GABAergic neurons projecting to the VTA helps promote but does not drive 
increased reward sensitivity.   
VTA GABAergic neurons project to other regions involved in reward, such as the 
NAc (Taylor et al., 2014) (Fig IV-1).  Activation of VTA GABAergic neurons 
synapsing onto cholinergic interneurons of the NAc leads to increased 
associative learning (Brown et al., 2012).  Conditioned place preference is a 
conditioning assay to train a subject to associate a chamber with a stimulus.  In 
this assay, Gad2VTA: Leu9´Ser exhibited a strong place preference to the 
chamber that was paired with 0.09 mg/kg nicotine, the dose shown to activate 
VTA GABAergic neurons (Chapter II).  Upregulation of α4* nAChRs VTA 
GABAergic neurons may strengthen nicotine associated cues such as the 
location where nicotine was administered through inhibition NAc cholinergic 
interneurons.  However, I was unable to detect α4* nAChRs in the NAc, possibly 
due to cholinergic interneurons being sparsely expressed in the striatum, 
therefore unable to confirm projections in this region (Chapter II) (Tepper and 
Bolam, 2004).  Furthermore, the amount of VTA GABAergic neurons projecting 
to the NAc appears to be small compared to the LHb (Taylor et al., 2014).  
Preliminary studies probing for choline acetyltransterase (ChAT) 
immunoreactivity were unsuccessful in my hands, but control experiments 
assessing antibody efficacy would identify if the Gad2-Cre driver line has a ChAT 
deficiency.. Although optogenetic studies suggest that cholinergic interneurons 
are important for cocaine-mediated reward (Witten et al., 2010), a small 
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population of neurons is unlikely to be the major driver of nicotine reward 
sensitivity. 
VTA GABAergic projections containing the Leu9´Se α4 nAChR subunit were not 
detected in the PFC (Chapter II).  However, this assessment is limited by the 
resolution of the YFP tag on the Leu9´Ser subunit as discussed above.  In fact, it 
is thought that putative VTA GABAergic projections to the PFC are responsible 
for associative learning.  It is suggested that information from the VTA to the PFC 
is transmitted immediately through GABA or glutamate and then modulated by 
DA, due to the slow modulatory behavior of DA and the expression of 
extrasynaptic DA receptors in the PFC (Kim et al., 2010).  The increase of high-
affinity nAChRs on these VTA GABA projection neurons to the PFC would 
improve GABA transmission and possibly heighten associative learning.  
Activation of Leu9´Ser α4* nAChRs on VTA GABAergic neurons may alter 
glutamatergic transmission to increase nicotine reward. The LDTg has been 
shown to be important for DAergic firing (Lodge and Grace, 2006) and provides a 
mixture of glutamatergic, GABAergic and cholinergic inputs to the VTA 
(Omelchenko and Sesack, 2005, 2006).  It is possible the release of 
acetylcholine, glutamate and GABA work in synchrony to activate VTA DAergic 
neurons.  VTA GABAergic neurons are activated by acetylcholine released by 
the LDTg to increase burst activity in DAergic neurons (Tolu et al., 2012), while 
glutamate and acetylcholine activate DAergic neurons.  Inducing burst activity in 
DAergic neurons may result in increased the AMPA/NMDA ratio in glutamatergic 
synapses and facilitating glutamatergic transmission (Saal et al., 2003).  
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Therefore, increasing activation of VTA GABAergic neurons through Leu9´Ser 
α4* nAChRs may further increase bursting activity, and further strengthen 
glutamatergic synapses on DAergic neurons, resulting in increased NAc DA 
concentrations.   
Overall, increased nicotine reward instigated by activating Leu9´Ser α4* nAChRs 
on VTA GABAergic neurons was induced by targeting as many pVTA GABAergic 
neurons as possible.  Being able to parse out how much a GABAergic neuronal 
subpopulation contributes to this outcome would provide a better understanding 
of how nicotine changes the VTA to encourage continued nicotine use.  Future 
studies looking at VTA GABAergic projections using of retrograde viral vector 
containing the Leu9´Ser α4 nAChR construct injected into the LHb, NAc or PFC 
would highlight the subset of VTA GABAergic neurons that provide input to the 
injected region.  This method would provide a better idea of the cytoarchitecture 
of the VTA, especially the organization of GABAergic neurons that project to a 
specific brain region.  Using 0.09 mg/kg nicotine to selective activate specific 
VTA GABAergic subpopulations based on projection region would dissect what 
percentage of VTA GABAergic neurons project to a particular region and the 
contribution of these particular neurons to increased nicotine reward.  However, 
this generalized approach may reflect what occurs with chronic nicotine 
exposure.  High-affinity nAChRs could possibly be upregulated on multiple VTA 
GABAergic subpopulations and the activation of these multiple pathways via 
nicotine promotes nicotine reward.  One way to define this phenomenon is the 
dysregulation of separate VTA GABAergic pathways.  The other way is to 
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suggest that upregulation of α4* nAChRs on multiple VTA GABAergic pathways 
produces an additive effect resulting in the enhancement of the rewarding 
properties of nicotine.   
 
IV.B. The role of increased expression of VTA GABAegic α4* nAChRs in anxiety 
Chapter III focuses on anxiety-like behaviors in an attempt to determine whether 
Leu9´Ser α4 nAChR subunit overexpression in VTA GABAergic neurons 
changes baseline anxiety levels or contributes to nicotine withdrawal symptoms.  
The rationale is as follows: smokers that eventually relapse exhibit intense 
negative affect feelings such as anxiety during nicotine withdrawal (Piasecki et 
al., 2000).  The VTA contains the necessary circuitry to induce negative affect 
either through directly activating VTA GABAergic neurons (van Zessen et al., 
2012; Tan et al., 2012) or by activating DAergic neurons that project to the PFC 
(Gunaydin et al., 2014).  Increased expression of Leu9´Ser α4* nAChRs can 
offset the normal VTA microcircuitry and induce anxiety-like behaviors through 
these anxiogenic pathways.  For example, heterozygous Leu9´Ser knock-in mice 
exhibit increased baseline anxiety-like behaviors (Labarca et al., 2001).  Despite 
the decrease of overall DAergic neurons in the Leu9´Ser knock-in mice, one can 
argue that the hypodopaminergic state in these mice reflects what occurs with 
increased functional expression of α4* nAChRs of VTA GABAergic neurons.  To 
test the hypothesis that overexpression of Leu9´Ser α4* nAChRs on VTA 
GABAergic neurons can promote anxiety-like behaviors, I assessed Gad2VTA: 
Leu9´Ser mice and control mice with three anxiety-like tests.  There were no 
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differences in Gad2VTA: Leu9´Ser behavioral activity compared to control, either 
locomotor or anxiety-related (Chapter III).  There is a non-significant trend for 
Gad2VTA: Leu9´Ser mice to exhibit anxiolytic behavior (Chapter III). Although I 
provide evidence supporting functional Leu9´Ser α4-YFP* nAChR are expressed 
in Gad2VTA: Leu9´Ser (Chapter II), appropriate controls need to be done to 
confirm these observations.  Activation of α4* nAChRs in chronic treated animals 
alleviates anxiety during withdrawal (Yohn et al., 2014).  However, other factors 
involved in anxiety modulated by chronic nicotine, such as CRF, may contribute 
to the nicotine withdrawal symptoms (Oliver et al., 2007; Grieder et al., 2014; 
Zhao-Shea et al., 2015).   
Nicotine induces locomotor activity changes in drug naïve mice (Marks et al., 
1983; Tapper et al., 2007).  However, the specific change differs from different 
strains of mice, as the C57BL/6, DBA and BALB mouse strain exhibited dose 
dependent hypolocomotor activity, while low doses of nicotine induced 
hyperlocomotor activity in C3H mice (Marks et al., 1983a; Schwartz and Kellar, 
1985).  The Gad2-Cre driver line was generated in the 129/Sv strain and was 
backcrossed to C57BL/6 at least twice.  Although subsequent backcrossing 
needs to be done to generate congenic mice, the Gad2-Cre strain exhibits 
hypolocomotion with 0.5 mg/kg nicotine, consistent with C57BL/6J mice (Marks 
et al., 1983a).  An acute injection of low doses of nicotine shown to selectively 
activate VTA GABAergic neurons drastically decreased locomotor activity in 
Gad2VTA: Leu9´Ser mice but not control mice (Chapter II). This effect was not due 
to a deficit in locomotor activity due to nAChR subunit overexpression, for there 
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was no significant difference in locomotor activity between Gad2VTA: Leu9´Ser 
and control mice (Chapter III).   Hypolocomotor activity in Gad2VTA: Leu9´Ser 
mice could be due to the anxiogenic properties of low doses of nicotine (Irvine et 
al., 2001; Biala and Budzynska, 2006).  Gad2VTA: Leu9´Ser but not control mice 
are prostrate on the cage floor within one minute of receiving an s.c. injection of 
0.09 mg/kg nicotine, with no overt movements other than breathing.  The 
instantaneous response to nicotine administration indicates that nicotine affects 
locomotor activity rather than affective behavior.  The hypolocomotor effect of 
nicotine may have no relevance to CPP because mice receive nicotine during the 
training period, where they are confined to a small chamber that does not allow 
much room for movement (Chapter II).  If anything, it may induce a negative 
association for the chamber, but ultimately does not deter the mouse from 
spending more time in the chamber post-training.   
Regardless of whether the hypolocomotor activity result from anxiety or deficits in 
locomotor activity, Gad2VTA: Leu9´Ser mice exhibited tolerance to nicotine over 
the span of 7 days as indicated by total locomotor activity recovering back to 
baseline (Chapter II), which coincides with the development of tolerance to the 
anxiogenic effects of nicotine 7 days after nicotine treatment (Biala and 
Budzynska, 2006).  These data suggest that activating VTA GABAergic neurons 
through α4* nAChRs is sufficient in inducing hypolocomotor activity and initiating 
tolerance.  It is hypothesized that chronic nicotine exposure increases α4* on 
VTA GABAergic neurons that inhibit pathways involved in motor suppression 
(Tapper et al., 2007).  On the other hand, intermittent exposure of nicotine 
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induced the functional upregulation of nAChRs in VTA DAergic neurons.  This 
observation coincides with the sensitization of locomotor activity, suggesting that 
sustained locomotor sensitization is due to increased nAChR activation on 
DAergic neurons (Baker et al., 2013).  These two models may represent two 
separate stages of drug dependence, with the upregulation of α4* nAChR 
receptors in VTA GABAergic neurons preceding nAChR upregulation of VTA 
DAergic neurons. Selectively inhibiting VTA GABAergic neurons either through 
optogenetic or chemogenetic techniques prior to nicotine administration would 
further test the hypothesis that VTA GABAergic transmission causes 
hypolocomotor activity and ultimately incites nicotine tolerance. 
Therefore, selectively activating VTA GABAergic neurons in Gad2VTA: Leu9´Ser 
mice would not help in assessing anxiety-like behaviors because drug naïve 
Gad2VTA: Leu9´Ser mice exhibit hypolocomotor activity immediately after nicotine 
administration (Chapter 2).  Anxiety tests are relatively short and the half-life of 
nicotine in a mouse is around 6 minutes (Petersen et al., 1984; Bourin and 
Hascoët, 2003; Matta et al., 2007; Walf and Frye, 2007; Brooks and Dunnett, 
2009),  so administering nicotine to Gad2VTA: Leu9´Ser mice prior to testing for 
anxiety-like behaviors would severely impact results.  Additionally, waiting for the 
mice to recover would not allow for the assessment of direct activation of VTA 
GABAergic neurons by nicotine. 
Nicotinic receptor antagonists, such as mecamylamine and DHβE, have been 
used to precipitate withdrawal in chronic nicotine treated rodents (Hildebrand et 
al., 1997; Damaj et al., 2003, Salas et al., 2004, 2009; Zhao-Shea et al., 2012, 
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2014).  Administering nicotinic receptor antagonists to nicotine naïve Gad2VTA: 
Leu9´Ser mice to measure somatic or affective withdrawal symptoms would 
highlight a subpopulation within the VTA involved in nicotine withdrawal 
symptoms.  There are several possible outcomes to this proposed experiment, 
and several important controls should be included.  The emergence of withdrawal 
symptoms in Gad2VTA: Leu9´Ser mice with nicotinic receptor antagonists would 
coincide with increased anxiety-like behaviors exhibited in the α4 KO mouse 
(Ross et al., 2000) and suggest activation of VTA GABAergic neurons dampens 
the intensity of withdrawal symptoms.  Alternatively, inactivating Leu9´Ser α4* 
nAChRs may lead to the decrease of anxiogenic behaviors through decreasing 
GABA transmission to other regions that provide glutamatergic input, such as the 
PFC (Fig. IV-1).  Glutamate transmission from the PFC increased DA activity 
(Murase et al., 1996) while restoring NMDA receptor expression in VTA DAergic 
neurons ameliorated anxiety-like behaviors brought on by fear conditioning 
(Zweifel et al., 2011).  These data indicate that glutamatergic activation of 
DAergic neurons can alleviate anxiety, and that inhibiting inhibitory afferents to 
these areas may result in disinhibition and the alleviation of anxiety.  Using a 
known anxiogenic or anxiolytic drug during the anxiety-like test would also 
confirm the face validity of the anxiety-like tests and provide an appropriate 
control to compare the effects observed in the experimental groups. 
Recent research indicates nAChRs in the habenulo-peduncular pathway are 
involved in nicotine withdrawal symptoms, framing the IPN as a prime nucleus for 
mediating both somatic and affective symptoms (Salas et al., 2004, 2009; Zhao-
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Shea et al., 2013, 2015).  Infusion of nAChR antagonist for α4β2 or α6β2 in the 
medial habenula (MHb) was sufficient to alleviate anxiety-like symptoms in mice 
withdrawn from nicotine, which coincided with increased expression of α4α6* 
nAChRs in the MHb (Pang et al., in review).  Knock out mice lacking specific 
subunits such as α2, α5 and β4 KO did not exhibit either spontaneous or 
precipitated nicotine mediated withdrawal symptoms (Salas et al., 2004, 2009).  
Interestingly enough, a connection between the VTA and the IPN has been 
recently observed, as CRF from VTA DAergic neurons is thought to activate 
CRF1 receptors in the IPN responsible for the anxiolytic effects signaled through 
the IPN (Grieder et al., 2014; Zhao-Shea et al., 2015).  It is possible that α4* 
nAChR upregulation reward signaling and anxiety signaling are two different 
pathways and the reward pathway feeds into the anxiety pathway.   
 
IV.C. Future Directions  
The Leu9´Ser α4-YFP nAChR gene expression system is a useful tool to allow 
for the cell-specific assessment of α4* nAChRs within a diverse neuronal brain 
region.  This technique tests the sufficiency of the α4 nAChR subunit within a 
certain component of the neuronal circuitry.  As described above, experiments 
detecting and quantifying the expression of the Leu9´Ser α4 nAChR subunit 
would further strengthen the observations made with this technique.  Several 
components of the system, such as the Cre-driver mouse line, also could be 
improved upon.  The current mouse driver lines available do not provide enough 
resolution to distinguish subpopulations within a particular group of neurons, 
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especially in the VTA.  It would be important to understand how these 
subpopulations could contribute to reward signaling in order to develop a 
comprehensive understanding of the workings of the VTA and better develop 
treatments that specifically target the subpopulation of cells that are responsible 
for the addictive properties of nicotine without upsetting the other neural 
connections that could decrease treatment efficacy.  Advanced recombinase 
regulated gene expression systems are currently under development that could 
further restrict expression of a gene based on Boolean logic (Fenno et al., 2014).  
This opens a whole avenue of honing into a specific neuronal subpopulation.  
Utilizing a neuron specific promoter such as synapsin can also reduce false 
positives by restricting expression exclusively in neurons (Kügler et a., 2003).  
These new developments in viral-mediated gene expression would refine our 
understanding of addiction- and withdrawal-relevant circuits in the brain.   
How does increasing α4 nAChR expression affect DAergic neuronal activation, 
and how does selectively activating VTA GABAergic neurons through α4* 
nAChRs modify DAergic activity?  Answering these two questions would provide 
a better idea behind the increase in nicotine reward sensitivity.  Chronic nicotine 
exposure decreased nicotine-mediated activation of VTA DAergic neurons while 
VTA GABAergic neurons exhibited increased activation with chronic nicotine 
exposure (Nashmi et al., 2007), suggesting that activation of upregulated α4* 
nAChRs in GABAergic neurons reduced activation of DAergic neurons by 
nicotine.  Although c-Fos studies suggest that DAergic neurons are not activated 
with 0.09 mg/kg nicotine (Chapter II), electrophysiological studies on DAergic 
 128 
neurons from Gad2VTA: Leu9´Ser brain slices would: 1) further confirm that low 
concentrations of nicotine do not activate DAergic neurons and more importantly 
2) determine if Leu9´Ser α4* VTA GABAergic interneurons decrease DAergic 
firing frequency upon application of a low does of nicotine.  The second 
experiment would further reveal what VTA GABAergic neuronal subpopulation 
contributes to increased nicotine reward sensitivity and further suggest that 
increasing α4* nAChR activation contributes to the shaping of DAergic burst 
firing activity (Tolu et al., 2014).  Measuring NAc DA concentrations through fast-
cyclic voltammetry would provide evidence to further suggest increased reward 
behavior observed in CPP is due to elevated DA concentrations in the NAc.   
Are the Leu9´Ser α4* nAChRs on VTA GABAergic neurons hypersensitive?  
Throughout this thesis, I refrained from referring to Leu9´Ser α4 nAChRs 
expressed via this system as hypersensitive because the appropriate tests were 
not done to confirm hypersensitivity.  The electrophysiological and 
immunohistochemical studies only demonstrate that the nAChRs expressed in 
VTA GABAergic neurons are “gain-of-function”, in that a single dose of nicotine 
increased current or c-Fos immunoreactivity over control samples (Chapter II).  
To confirm hypersensitivity, either voltage clamp recordings or c-Fos 
immunostaining in response to a series of nicotine doses would be needed.  
Three nicotine doses were tested in the CPP assays, but these studies do not 
show what occurs at the molecular and cellular level (Chapter II).  Additional 
doses, especially lower doses would further assess the hypersensitive nature of 
the Leu9´Ser α4* nAChR in the Gad2VTA: Leu9´Ser model.   
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The dose of 0.09 mg/kg nicotine was derived from previous studies (McGeehan 
and Olive, 2003; Brunzell et al., 2009) that elicited CPP in C57BL/6 mice.  One 
may ask why 0.09 mg/kg dose was insufficient to induce reward in Gad2-Cre 
mice that are assumed to be on a C57BL/6 background or why 0.5 mg/kg 
nicotine failed to elicit CPP in control or Gad2VTA: Leu9´Ser mice (Chapter II).  It 
is possible the Gad2-Cre driver line has 129/Sv strain properties that may confer 
nicotine insensitivity.  Additionally, variation in handling and administration can 
factor into overall CPP expression (Matta et al., 2007).  Assessing the expression 
of nAChRs in the Gad2-Cre line versus a C57BL/6 line would confirm the nAChR 
profile and determine if Leu9´Ser α4 expression is compensating for low α4 
nAChR expression.  To complement these studies, overexpressing non-mutant 
α4-YFP nAChR subunits in Gad2-Cre mice address this issue rather than ChR2-
YFP.  
Human genome studies have implicated rs1044396 C single nucleotide 
polymorphism in the CHRNA4 gene in increasing the hedonistic effects of 
smoking, the exacerbation of negative affective behaviors as well as the 
likelihood to develop nicotine dependence (Feng et al., 2004; Markett et al., 
2011; Tsai et al., 2012; Lazary et al., 2014).  Studies in Xenopus oocytes injected 
with α4 receptors with different exon 5 haplotypes observed nicotine activation of 
cells expressing the rs1044396 C allele at lower nicotine concentrations 
compared to the T allele (Winterer et al., 2011).  Designing a viral construct 
containing the appropriate single nucleotide polymorphism, similar to the α5 
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D398N experiments of Morel and colleagues could provide molecular insight into 
the mutation (Morel et al., 2013).  Infusing viral particles into either Gad2-Cre or 
α4 KO mice specifically in the VTA, IPN or MHb would also further help 
determine how these CHRNA4 variants alter overall receptor function. 
Nicotine is known to be co-abused with other drugs of abuse, such as alcohol. 
Alcohol does not have a well-defined target to act upon in order to signal reward.  
However, α4* nAChRs have been shown to be important for the rewarding 
properties of alcohol (Henderickson et al., 2010).  It is thought that alcohol acts 
through indirect and allosteric methods to induce nAChR activation and induce 
reward.  It could be that increasing α4* nAChR expression on VTA GABAergic 
neurons can also increase sensitivity to alcohol reward.  Other drugs of abuse, 
such as cocaine, appear to act on mechanisms independent of nAChRs 
(McGranahan et al., 2011), but it is possible that α4* nAChR upregulation can 
potentiate the response to low levels of cocaine and induce reward.  Using 
Gad2VTA: Leu9´Ser mice during the appropriate reward assays with these drugs 
would help elucidate this part. 
A disproportionate amount of smokers also have a neuropsychiatric disorder, 
(Annamalai et al., 2015).  This is an issue when dealing with smoking cessation, 
as complications can arise from other medications used in concurrence with 
smoking cessation. Increasing cholinergic activation through inhibiting 
neurotransmitter breakdown has been shown to play a role in eliciting manic 
behaviors (Janowsky 1978, Risch 1981).  Acting upon nAChRs either with 
antagonists or partial agonist have yielded promising effects in treating the 
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symptoms associated with depression and anxiety (Rolema et al., 2009; 
Patterson et al., 2009; Turner et al 2010; Yohn et al., 2014).  It is hypothesized 
that aberrant DA activity, particularly in the VTA, can lead to various psychiatric 
disorders such as schizophrenia and depression (Lodge and Grace, 2011).  
Smoking may provide an avenue for neuropsychiatric patients to regulate 
DAergic activity, because a smoker can titrate the amount of nicotine they 
receive through the number of puffs from a cigarette they take. Indeed, studies 
assessing the effects of smoking history in reward responsiveness in depressed 
individuals indicated that depressed individuals without a history of smoking 
performed worst than those in control, while depressed individuals with a history 
of smoking exhibited reward responsiveness similar to control (Janes et al., 
2015).  These data imply that smoking at least in depressed individuals is a 
method of therapy to counteract the negative state.  Further studies into 
understanding how VTA GABAergic specific α4* nAChR upregulation affects 
circuits involved with reward and aversion may provide valuable insight into novel 
therapies to treat neuropsychiatric disorders.  
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